<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1996-10-01" modified="2020-10-07" version="238">
<accession>P49768</accession>
<accession>B2R6D3</accession>
<accession>O95465</accession>
<accession>Q14762</accession>
<accession>Q15719</accession>
<accession>Q15720</accession>
<accession>Q96P33</accession>
<accession>Q9UIF0</accession>
<name>PSN1_HUMAN</name>
<protein>
<recommendedName>
<fullName>Presenilin-1</fullName>
<shortName>PS-1</shortName>
<ecNumber evidence="20 31 32 51 57 97">3.4.23.-</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Protein S182</fullName>
</alternativeName>
<component>
<recommendedName>
<fullName>Presenilin-1 NTF subunit</fullName>
</recommendedName>
</component>
<component>
<recommendedName>
<fullName>Presenilin-1 CTF subunit</fullName>
</recommendedName>
</component>
<component>
<recommendedName>
<fullName>Presenilin-1 CTF12</fullName>
<shortName>PS1-CTF12</shortName>
</recommendedName>
</component>
</protein>
<gene>
<name type="primary">PSEN1</name>
<name type="synonym">AD3</name>
<name type="synonym">PS1</name>
<name type="synonym">PSNL1</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1995" name="Nature" volume="375" first="754" last="760">
<title>Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.</title>
<authorList>
<person name="Sherrington R."/>
<person name="Rogaev E.I."/>
<person name="Liang Y."/>
<person name="Rogaeva E.A."/>
<person name="Levesque G."/>
<person name="Ikeda M."/>
<person name="Chi H."/>
<person name="Lin C."/>
<person name="Li G."/>
<person name="Holman K."/>
<person name="Tsuda T."/>
<person name="Mar L."/>
<person name="Foncin J.-F."/>
<person name="Bruni A.C."/>
<person name="Montesi M.P."/>
<person name="Sorbi S."/>
<person name="Rainero I."/>
<person name="Pinessi L."/>
<person name="Nee L."/>
<person name="Chumakov I."/>
<person name="Pollen D."/>
<person name="Brookes A."/>
<person name="Sanseau P."/>
<person name="Polinsky R.J."/>
<person name="Wasco W."/>
<person name="da Silva H.A.R."/>
<person name="Haines J.L."/>
<person name="Pericak-Vance M.A."/>
<person name="Tanzi R.E."/>
<person name="Roses A.D."/>
<person name="Fraser P.E."/>
<person name="Rommens J.M."/>
<person name="St George-Hyslop P.H."/>
</authorList>
<dbReference type="PubMed" id="7596406"/>
<dbReference type="DOI" id="10.1038/375754a0"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2)</scope>
<scope>VARIANTS AD3 LEU-146; ARG-163; GLU-246 AND VAL-286</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="1996" name="FEBS Lett." volume="381" first="7" last="11">
<title>Identification and characterization of presenilin I-467, I-463 and I-374.</title>
<authorList>
<person name="Sahara N."/>
<person name="Yahagi Y."/>
<person name="Takagi H."/>
<person name="Kondo T."/>
<person name="Okochi M."/>
<person name="Usami M."/>
<person name="Shirasawa T."/>
<person name="Mori H."/>
</authorList>
<dbReference type="PubMed" id="8641442"/>
<dbReference type="DOI" id="10.1016/0014-5793(96)00054-3"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3)</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Blood</tissue>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="3">
<citation type="submission" date="1998-08" db="EMBL/GenBank/DDBJ databases">
<title>Human presenilin 1 gene encodes an alternative protein-minilin.</title>
<authorList>
<person name="Powell C.S."/>
<person name="Gegg M.E."/>
<person name="Palmer M.S."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4)</scope>
</reference>
<reference key="4">
<citation type="submission" date="1998-11" db="EMBL/GenBank/DDBJ databases">
<title>Complete sequence of the gene for presenilin 1.</title>
<authorList>
<person name="Rowen L."/>
<person name="Madan A."/>
<person name="Qin S."/>
<person name="Abbasi N."/>
<person name="Dors M."/>
<person name="Ratcliffe A."/>
<person name="Madan A."/>
<person name="Dickhoff R."/>
<person name="Shaffer T."/>
<person name="James R."/>
<person name="Lasky S."/>
<person name="Hood L."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="5">
<citation type="submission" date="2001-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Kang L."/>
<person name="Zhang B."/>
<person name="Zhou Y."/>
<person name="Peng X."/>
<person name="Yuan J."/>
<person name="Qiang B."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5)</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Tongue</tissue>
</source>
</reference>
<reference key="7">
<citation type="journal article" date="2003" name="Nature" volume="421" first="601" last="607">
<title>The DNA sequence and analysis of human chromosome 14.</title>
<authorList>
<person name="Heilig R."/>
<person name="Eckenberg R."/>
<person name="Petit J.-L."/>
<person name="Fonknechten N."/>
<person name="Da Silva C."/>
<person name="Cattolico L."/>
<person name="Levy M."/>
<person name="Barbe V."/>
<person name="De Berardinis V."/>
<person name="Ureta-Vidal A."/>
<person name="Pelletier E."/>
<person name="Vico V."/>
<person name="Anthouard V."/>
<person name="Rowen L."/>
<person name="Madan A."/>
<person name="Qin S."/>
<person name="Sun H."/>
<person name="Du H."/>
<person name="Pepin K."/>
<person name="Artiguenave F."/>
<person name="Robert C."/>
<person name="Cruaud C."/>
<person name="Bruels T."/>
<person name="Jaillon O."/>
<person name="Friedlander L."/>
<person name="Samson G."/>
<person name="Brottier P."/>
<person name="Cure S."/>
<person name="Segurens B."/>
<person name="Aniere F."/>
<person name="Samain S."/>
<person name="Crespeau H."/>
<person name="Abbasi N."/>
<person name="Aiach N."/>
<person name="Boscus D."/>
<person name="Dickhoff R."/>
<person name="Dors M."/>
<person name="Dubois I."/>
<person name="Friedman C."/>
<person name="Gouyvenoux M."/>
<person name="James R."/>
<person name="Madan A."/>
<person name="Mairey-Estrada B."/>
<person name="Mangenot S."/>
<person name="Martins N."/>
<person name="Menard M."/>
<person name="Oztas S."/>
<person name="Ratcliffe A."/>
<person name="Shaffer T."/>
<person name="Trask B."/>
<person name="Vacherie B."/>
<person name="Bellemere C."/>
<person name="Belser C."/>
<person name="Besnard-Gonnet M."/>
<person name="Bartol-Mavel D."/>
<person name="Boutard M."/>
<person name="Briez-Silla S."/>
<person name="Combette S."/>
<person name="Dufosse-Laurent V."/>
<person name="Ferron C."/>
<person name="Lechaplais C."/>
<person name="Louesse C."/>
<person name="Muselet D."/>
<person name="Magdelenat G."/>
<person name="Pateau E."/>
<person name="Petit E."/>
<person name="Sirvain-Trukniewicz P."/>
<person name="Trybou A."/>
<person name="Vega-Czarny N."/>
<person name="Bataille E."/>
<person name="Bluet E."/>
<person name="Bordelais I."/>
<person name="Dubois M."/>
<person name="Dumont C."/>
<person name="Guerin T."/>
<person name="Haffray S."/>
<person name="Hammadi R."/>
<person name="Muanga J."/>
<person name="Pellouin V."/>
<person name="Robert D."/>
<person name="Wunderle E."/>
<person name="Gauguet G."/>
<person name="Roy A."/>
<person name="Sainte-Marthe L."/>
<person name="Verdier J."/>
<person name="Verdier-Discala C."/>
<person name="Hillier L.W."/>
<person name="Fulton L."/>
<person name="McPherson J."/>
<person name="Matsuda F."/>
<person name="Wilson R."/>
<person name="Scarpelli C."/>
<person name="Gyapay G."/>
<person name="Wincker P."/>
<person name="Saurin W."/>
<person name="Quetier F."/>
<person name="Waterston R."/>
<person name="Hood L."/>
<person name="Weissenbach J."/>
</authorList>
<dbReference type="PubMed" id="12508121"/>
<dbReference type="DOI" id="10.1038/nature01348"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="8">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)</scope>
<source>
<tissue>Skin</tissue>
</source>
</reference>
<reference key="10">
<citation type="journal article" date="1997" name="Biochem. Biophys. Res. Commun." volume="231" first="392" last="396">
<title>Cloning of Xenopus presenilin-alpha and -beta cDNAs and their differential expression in oogenesis and embryogenesis.</title>
<authorList>
<person name="Tsujimura A."/>
<person name="Yasojima K."/>
<person name="Hashimoto-Gotoh T."/>
</authorList>
<dbReference type="PubMed" id="9070286"/>
<dbReference type="DOI" id="10.1006/bbrc.1996.6043"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-113</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1996" name="FEBS Lett." volume="393" first="19" last="23">
<title>Alzheimer's presenilin 1 gene expression in platelets and megakaryocytes. Identification of a novel splice variant.</title>
<authorList>
<person name="Vidal R."/>
<person name="Ghiso J."/>
<person name="Wisniewski T."/>
<person name="Frangione B."/>
</authorList>
<dbReference type="PubMed" id="8804415"/>
<dbReference type="DOI" id="10.1016/0014-5793(96)00845-9"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 24-32</scope>
<scope>ALTERNATIVE SPLICING (ISOFORMS 6 AND 7)</scope>
<source>
<tissue>Megakaryocyte</tissue>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="12">
<citation type="journal article" date="2004" name="Biochemistry" volume="43" first="9774" last="9789">
<title>Purification and characterization of the human gamma-secretase complex.</title>
<authorList>
<person name="Fraering P.C."/>
<person name="Ye W."/>
<person name="Strub J.-M."/>
<person name="Dolios G."/>
<person name="LaVoie M.J."/>
<person name="Ostaszewski B.L."/>
<person name="van Dorsselaer A."/>
<person name="Wang R."/>
<person name="Selkoe D.J."/>
<person name="Wolfe M.S."/>
</authorList>
<dbReference type="PubMed" id="15274632"/>
<dbReference type="DOI" id="10.1021/bi0494976"/>
</citation>
<scope>PROTEIN SEQUENCE OF 36-42; 61-76; 109-129; 217-239; 270-278; 315-320; 345-352 AND 381-395 (ISOFORM 1)</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>IDENTIFICATION IN GAMMA-SECRETASE COMPLEX</scope>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1996" name="Nat. Med." volume="2" first="224" last="229">
<title>Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells.</title>
<authorList>
<person name="Kovacs D.M."/>
<person name="Fausett H.J."/>
<person name="Page K.J."/>
<person name="Kim T.-W."/>
<person name="Moir R.D."/>
<person name="Merriam D.E."/>
<person name="Hollister R.D."/>
<person name="Hallmark O.G."/>
<person name="Mancini R."/>
<person name="Felsenstein K.M."/>
<person name="Hyman B.T."/>
<person name="Tanzi R.E."/>
<person name="Wasco W."/>
</authorList>
<dbReference type="PubMed" id="8574969"/>
<dbReference type="DOI" id="10.1038/nm0296-224"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1997" name="Neurobiol. Dis." volume="3" first="325" last="337">
<title>Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue.</title>
<authorList>
<person name="Podlisny M.B."/>
<person name="Citron M."/>
<person name="Amarante P."/>
<person name="Sherrington R."/>
<person name="Xia W."/>
<person name="Zhang J."/>
<person name="Diehl T."/>
<person name="Levesque G."/>
<person name="Fraser P."/>
<person name="Haass C."/>
<person name="Koo E.H."/>
<person name="Seubert P."/>
<person name="St George-Hyslop P.H."/>
<person name="Teplow D.B."/>
<person name="Selkoe D.J."/>
</authorList>
<dbReference type="PubMed" id="9173929"/>
<dbReference type="DOI" id="10.1006/nbdi.1997.0129"/>
</citation>
<scope>PROTEOLYTIC PROCESSING</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1997" name="Proc. Natl. Acad. Sci. U.S.A." volume="94" first="5349" last="5354">
<title>Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C.</title>
<authorList>
<person name="Walter J."/>
<person name="Gruenberg J."/>
<person name="Capell A."/>
<person name="Pesold B."/>
<person name="Schindzielorz A."/>
<person name="Citron M."/>
<person name="Mendla K."/>
<person name="St George-Hyslop P.H."/>
<person name="Multhaup G."/>
<person name="Selkoe D.J."/>
<person name="Haass C."/>
</authorList>
<dbReference type="PubMed" id="9144240"/>
<dbReference type="DOI" id="10.1073/pnas.94.10.5349"/>
</citation>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1998" name="Biochemistry" volume="37" first="2263" last="2270">
<title>Alzheimer's disease associated presenilin-1 holoprotein and its 18-20 kDa C-terminal fragment are death substrates for proteases of the caspase family.</title>
<authorList>
<person name="Gruenberg J."/>
<person name="Walter J."/>
<person name="Loetscher H."/>
<person name="Deuschle U."/>
<person name="Jacobsen H."/>
<person name="Haass C."/>
</authorList>
<dbReference type="PubMed" id="9485372"/>
<dbReference type="DOI" id="10.1021/bi972106l"/>
</citation>
<scope>CASPASE CLEAVAGE SITE</scope>
<scope>MUTAGENESIS OF ASP-345; ASP-373 AND ASP-385</scope>
</reference>
<reference key="17">
<citation type="journal article" date="1998" name="FEBS Lett." volume="433" first="73" last="77">
<title>Direct association of presenilin-1 with beta-catenin.</title>
<authorList>
<person name="Murayama M."/>
<person name="Tanaka S."/>
<person name="Palacino J."/>
<person name="Murayama O."/>
<person name="Honda T."/>
<person name="Sun X."/>
<person name="Yasutake K."/>
<person name="Nihonmatsu N."/>
<person name="Wolozin B."/>
<person name="Takashima A."/>
</authorList>
<dbReference type="PubMed" id="9738936"/>
<dbReference type="DOI" id="10.1016/s0014-5793(98)00886-2"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH CTNNB1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="18">
<citation type="journal article" date="1998" name="J. Neurosci." volume="18" first="914" last="922">
<title>Interaction of presenilins with the filamin family of actin-binding proteins.</title>
<authorList>
<person name="Zhang W."/>
<person name="Han S.W."/>
<person name="McKeel D.W."/>
<person name="Goate A."/>
<person name="Wu J.Y."/>
</authorList>
<dbReference type="PubMed" id="9437013"/>
<dbReference type="DOI" id="10.1523/jneurosci.18-03-00914.1998"/>
</citation>
<scope>INTERACTION WITH FLNA AND FLNB</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1999" name="Biochemistry" volume="38" first="14600" last="14605">
<title>Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis.</title>
<authorList>
<person name="Steiner H."/>
<person name="Romig H."/>
<person name="Pesold B."/>
<person name="Philipp U."/>
<person name="Baader M."/>
<person name="Citron M."/>
<person name="Loetscher H."/>
<person name="Jacobsen H."/>
<person name="Haass C."/>
</authorList>
<dbReference type="PubMed" id="10545183"/>
<dbReference type="DOI" id="10.1021/bi9914210"/>
</citation>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF MET-292</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="32543" last="32546">
<title>Identification of a novel PSD-95/Dlg/ZO-1 (PDZ)-like protein interacting with the C terminus of presenilin-1.</title>
<authorList>
<person name="Xu X."/>
<person name="Shi Y.-C."/>
<person name="Wu X."/>
<person name="Gambetti P."/>
<person name="Sui D."/>
<person name="Cui M.-Z."/>
</authorList>
<dbReference type="PubMed" id="10551805"/>
<dbReference type="DOI" id="10.1074/jbc.274.46.32543"/>
</citation>
<scope>INTERACTION WITH MTCH1</scope>
</reference>
<reference key="21">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="36801" last="36807">
<title>Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch.</title>
<authorList>
<person name="Ray W.J."/>
<person name="Yao M."/>
<person name="Mumm J."/>
<person name="Schroeter E.H."/>
<person name="Saftig P."/>
<person name="Wolfe M."/>
<person name="Selkoe D.J."/>
<person name="Kopan R."/>
<person name="Goate A.M."/>
</authorList>
<dbReference type="PubMed" id="10593990"/>
<dbReference type="DOI" id="10.1074/jbc.274.51.36801"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH NOTCH</scope>
</reference>
<reference key="22">
<citation type="journal article" date="1999" name="J. Neurochem." volume="72" first="999" last="1008">
<title>Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin.</title>
<authorList>
<person name="Levesque G."/>
<person name="Yu G."/>
<person name="Nishimura M."/>
<person name="Zhang D.M."/>
<person name="Levesque L."/>
<person name="Yu H."/>
<person name="Xu D."/>
<person name="Liang Y."/>
<person name="Rogaeva E.A."/>
<person name="Ikeda M."/>
<person name="Duthie M."/>
<person name="Murgolo N."/>
<person name="Wang L."/>
<person name="VanderVere P."/>
<person name="Bayne M.L."/>
<person name="Strader C.D."/>
<person name="Rommens J.M."/>
<person name="Fraser P.E."/>
<person name="St George-Hyslop P.H."/>
</authorList>
<dbReference type="PubMed" id="10037471"/>
<dbReference type="DOI" id="10.1046/j.1471-4159.1999.0720999.x"/>
</citation>
<scope>INTERACTION WITH CTNND2 AND CTNNB1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="1999" name="Nature" volume="398" first="513" last="517">
<title>Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.</title>
<authorList>
<person name="Wolfe M.S."/>
<person name="Xia W."/>
<person name="Ostaszewski B.L."/>
<person name="Diehl T.S."/>
<person name="Kimberly W.T."/>
<person name="Selkoe D.J."/>
</authorList>
<dbReference type="PubMed" id="10206644"/>
<dbReference type="DOI" id="10.1038/19077"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF ASP-257 AND ASP-385</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2000" name="J. Neurochem." volume="75" first="583" last="593">
<title>Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.</title>
<authorList>
<person name="Berezovska O."/>
<person name="Jack C."/>
<person name="McLean P."/>
<person name="Aster J.C."/>
<person name="Hicks C."/>
<person name="Xia W."/>
<person name="Wolfe M.S."/>
<person name="Kimberly W.T."/>
<person name="Weinmaster G."/>
<person name="Selkoe D.J."/>
<person name="Hyman B.T."/>
</authorList>
<dbReference type="PubMed" id="10899933"/>
<dbReference type="DOI" id="10.1046/j.1471-4159.2000.0750583.x"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF ASP-257 AND ASP-385</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2000" name="Proc. Natl. Acad. Sci. U.S.A." volume="97" first="5913" last="5918">
<title>Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch.</title>
<authorList>
<person name="Kulic L."/>
<person name="Walter J."/>
<person name="Multhaup G."/>
<person name="Teplow D.B."/>
<person name="Baumeister R."/>
<person name="Romig H."/>
<person name="Capell A."/>
<person name="Steiner H."/>
<person name="Haass C."/>
</authorList>
<dbReference type="PubMed" id="10811883"/>
<dbReference type="DOI" id="10.1073/pnas.100049897"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF LEU-286</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Blood Cells Mol. Dis." volume="28" first="28" last="38">
<title>Identification of the presenilins in hematopoietic cells with localization of presenilin 1 to neutrophil and platelet granules.</title>
<authorList>
<person name="Mirinics Z.K."/>
<person name="Calafat J."/>
<person name="Udby L."/>
<person name="Lovelock J."/>
<person name="Kjeldsen L."/>
<person name="Rothermund K."/>
<person name="Sisodia S.S."/>
<person name="Borregaard N."/>
<person name="Corey S.J."/>
</authorList>
<dbReference type="PubMed" id="11987239"/>
<dbReference type="DOI" id="10.1006/bcmd.2002.0486"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2002" name="EMBO J." volume="21" first="1948" last="1956">
<title>A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions.</title>
<authorList>
<person name="Marambaud P."/>
<person name="Shioi J."/>
<person name="Serban G."/>
<person name="Georgakopoulos A."/>
<person name="Sarner S."/>
<person name="Nagy V."/>
<person name="Baki L."/>
<person name="Wen P."/>
<person name="Efthimiopoulos S."/>
<person name="Shao Z."/>
<person name="Wisniewski T."/>
<person name="Robakis N.K."/>
</authorList>
<dbReference type="PubMed" id="11953314"/>
<dbReference type="DOI" id="10.1093/emboj/21.8.1948"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH CDH1 AND CTNNB1</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="12915" last="12920">
<title>Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein.</title>
<authorList>
<person name="Sai X."/>
<person name="Kawamura Y."/>
<person name="Kokame K."/>
<person name="Yamaguchi H."/>
<person name="Shiraishi H."/>
<person name="Suzuki R."/>
<person name="Suzuki T."/>
<person name="Kawaichi M."/>
<person name="Miyata T."/>
<person name="Kitamura T."/>
<person name="De Strooper B."/>
<person name="Yanagisawa K."/>
<person name="Komano H."/>
</authorList>
<dbReference type="PubMed" id="11799129"/>
<dbReference type="DOI" id="10.1074/jbc.m112372200"/>
</citation>
<scope>INTERACTION WITH HERPUD1</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="29983" last="29991">
<title>A new splice variant of glial fibrillary acidic protein GFAPepsilon, interacts with the presenilin proteins.</title>
<authorList>
<person name="Nielsen A.L."/>
<person name="Holm I.E."/>
<person name="Johansen M."/>
<person name="Bonven B."/>
<person name="Jorgensen P."/>
<person name="Jorgensen A.L."/>
</authorList>
<dbReference type="PubMed" id="12058025"/>
<dbReference type="DOI" id="10.1074/jbc.m112121200"/>
</citation>
<scope>INTERACTION WITH GFAP</scope>
<scope>MUTAGENESIS OF 66-ASP--ASP-72; 76-LYS-TYR-77; 82-VAL-ILE-83; VAL-82 AND 84-MET-LEU-85</scope>
<scope>CHARACTERIZATION OF VARIANTS AD3 VAL-79 AND LEU-82</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2003" name="J. Neurosci. Res." volume="74" first="184" last="191">
<title>Presenilin 1 is involved in maturation and trafficking of N-cadherin to the plasma membrane.</title>
<authorList>
<person name="Uemura K."/>
<person name="Kitagawa N."/>
<person name="Kohno R."/>
<person name="Kuzuya A."/>
<person name="Kageyama T."/>
<person name="Chonabayashi K."/>
<person name="Shibasaki H."/>
<person name="Shimohama S."/>
</authorList>
<dbReference type="PubMed" id="14515347"/>
<dbReference type="DOI" id="10.1002/jnr.10753"/>
</citation>
<scope>INTERACTION WITH CDH2</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>MUTAGENESIS OF ASP-385</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2003" name="Nat. Cell Biol." volume="5" first="486" last="488">
<title>Reconstitution of gamma-secretase activity.</title>
<authorList>
<person name="Edbauer D."/>
<person name="Winkler E."/>
<person name="Regula J.T."/>
<person name="Pesold B."/>
<person name="Steiner H."/>
<person name="Haass C."/>
</authorList>
<dbReference type="PubMed" id="12679784"/>
<dbReference type="DOI" id="10.1038/ncb960"/>
</citation>
<scope>ENZYME ACTIVITY OF A GAMMA-SECRETASE COMPLEX</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2003" name="Proc. Natl. Acad. Sci. U.S.A." volume="100" first="6382" last="6387">
<title>Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2.</title>
<authorList>
<person name="Kimberly W.T."/>
<person name="LaVoie M.J."/>
<person name="Ostaszewski B.L."/>
<person name="Ye W."/>
<person name="Wolfe M.S."/>
<person name="Selkoe D.J."/>
</authorList>
<dbReference type="PubMed" id="12740439"/>
<dbReference type="DOI" id="10.1073/pnas.1037392100"/>
</citation>
<scope>COMPONENT OF A GAMMA-SECRETASE COMPLEX WITH PEN2; PSEN1/PSEN2 AND NCSTN</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="Genome Biol." volume="5" first="R8.1" last="R8.16">
<title>An unappreciated role for RNA surveillance.</title>
<authorList>
<person name="Hillman R.T."/>
<person name="Green R.E."/>
<person name="Brenner S.E."/>
</authorList>
<dbReference type="PubMed" id="14759258"/>
<dbReference type="DOI" id="10.1186/gb-2004-5-2-r8"/>
</citation>
<scope>SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S)</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2004" name="J. Alzheimers Dis." volume="6" first="31" last="43">
<title>A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations.</title>
<authorList>
<person name="Dowjat W.K."/>
<person name="Kuchna I."/>
<person name="Wisniewski T."/>
<person name="Wegiel J."/>
</authorList>
<dbReference type="PubMed" id="15004326"/>
<dbReference type="DOI" id="10.3233/jad-2004-6105"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>VARIANT AD3 SER-117</scope>
<scope>CHARACTERIZATION OF VARIANTS AD3 LEU-117 AND SER-117</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="1585" last="1593">
<title>Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis.</title>
<authorList>
<person name="Fluhrer R."/>
<person name="Friedlein A."/>
<person name="Haass C."/>
<person name="Walter J."/>
</authorList>
<dbReference type="PubMed" id="14576165"/>
<dbReference type="DOI" id="10.1074/jbc.m306653200"/>
</citation>
<scope>PHOSPHORYLATION AT SER-310 AND SER-346</scope>
<scope>MUTAGENESIS OF SER-310 AND SER-346</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="50790" last="50798">
<title>Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins.</title>
<authorList>
<person name="Friedmann E."/>
<person name="Lemberg M.K."/>
<person name="Weihofen A."/>
<person name="Dev K.K."/>
<person name="Dengler U."/>
<person name="Rovelli G."/>
<person name="Martoglio B."/>
</authorList>
<dbReference type="PubMed" id="15385547"/>
<dbReference type="DOI" id="10.1074/jbc.m407898200"/>
</citation>
<scope>TOPOLOGY</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2004" name="J. Neurochem." volume="90" first="1312" last="1320">
<title>Conserved residues within the putative active site of gamma-secretase differentially influence enzyme activity and inhibitor binding.</title>
<authorList>
<person name="Wrigley J.D."/>
<person name="Nunn E.J."/>
<person name="Nyabi O."/>
<person name="Clarke E.E."/>
<person name="Hunt P."/>
<person name="Nadin A."/>
<person name="De Strooper B."/>
<person name="Shearman M.S."/>
<person name="Beher D."/>
</authorList>
<dbReference type="PubMed" id="15341515"/>
<dbReference type="DOI" id="10.1111/j.1471-4159.2004.02596.x"/>
</citation>
<scope>FUNCTION</scope>
<scope>ACTIVE SITES ASP-257 AND ASP-385</scope>
<scope>MUTAGENESIS OF TYR-256; ASP-257; ASP-385 AND TYR-389</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="36007" last="36012">
<title>Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability.</title>
<authorList>
<person name="Serban G."/>
<person name="Kouchi Z."/>
<person name="Baki L."/>
<person name="Georgakopoulos A."/>
<person name="Litterst C.M."/>
<person name="Shioi J."/>
<person name="Robakis N.K."/>
</authorList>
<dbReference type="PubMed" id="16126725"/>
<dbReference type="DOI" id="10.1074/jbc.m507503200"/>
</citation>
<scope>INTERACTION WITH CDH1 AND CTNNB1</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2006" name="Cell" volume="127" first="635" last="648">
<title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
<person name="Gnad F."/>
<person name="Macek B."/>
<person name="Kumar C."/>
<person name="Mortensen P."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="17081983"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.09.026"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="40">
<citation type="journal article" date="2006" name="Cell" volume="126" first="981" last="993">
<title>Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.</title>
<authorList>
<person name="Tu H."/>
<person name="Nelson O."/>
<person name="Bezprozvanny A."/>
<person name="Wang Z."/>
<person name="Lee S.F."/>
<person name="Hao Y.H."/>
<person name="Serneels L."/>
<person name="De Strooper B."/>
<person name="Yu G."/>
<person name="Bezprozvanny I."/>
</authorList>
<dbReference type="PubMed" id="16959576"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.06.059"/>
</citation>
<scope>FUNCTION</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 VAL-146</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2006" name="J. Neurochem." volume="96" first="218" last="227">
<title>C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation.</title>
<authorList>
<person name="Wang J."/>
<person name="Beher D."/>
<person name="Nyborg A.C."/>
<person name="Shearman M.S."/>
<person name="Golde T.E."/>
<person name="Goate A."/>
</authorList>
<dbReference type="PubMed" id="16305624"/>
<dbReference type="DOI" id="10.1111/j.1471-4159.2005.03548.x"/>
</citation>
<scope>FUNCTION OF PAL MOTIF</scope>
<scope>MUTAGENESIS OF PRO-433; ALA-434 AND LEU-435</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 PHE-435</scope>
</reference>
<reference key="42">
<citation type="journal article" date="1996" name="Hum. Mol. Genet." volume="5" first="1449" last="1455">
<title>The presenilin genes: a new gene family involved in Alzheimer disease pathology.</title>
<authorList>
<person name="Cruts M."/>
<person name="Hendriks L."/>
<person name="Van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="8875251"/>
<dbReference type="DOI" id="10.1093/hmg/5.supplement_1.1449"/>
</citation>
<scope>REVIEW ON VARIANTS</scope>
</reference>
<reference key="43">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="11" first="183" last="190">
<title>Presenilin mutations in Alzheimer's disease.</title>
<authorList>
<person name="Cruts M."/>
<person name="van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="9521418"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1998)11:3&lt;183::aid-humu1&gt;3.0.co;2-j"/>
</citation>
<scope>REVIEW ON VARIANTS</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2008" name="Mol. Cell" volume="31" first="438" last="448">
<title>Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.</title>
<authorList>
<person name="Daub H."/>
<person name="Olsen J.V."/>
<person name="Bairlein M."/>
<person name="Gnad F."/>
<person name="Oppermann F.S."/>
<person name="Korner R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Stemmann O."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="18691976"/>
<dbReference type="DOI" id="10.1016/j.molcel.2008.07.007"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="45">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="46">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="47">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="48">
<citation type="journal article" date="2010" name="Science" volume="330" first="1065" last="1065">
<title>Gamma-secretase gene mutations in familial acne inversa.</title>
<authorList>
<person name="Wang B."/>
<person name="Yang W."/>
<person name="Wen W."/>
<person name="Sun J."/>
<person name="Su B."/>
<person name="Liu B."/>
<person name="Ma D."/>
<person name="Lv D."/>
<person name="Wen Y."/>
<person name="Qu T."/>
<person name="Chen M."/>
<person name="Sun M."/>
<person name="Shen Y."/>
<person name="Zhang X."/>
</authorList>
<dbReference type="PubMed" id="20929727"/>
<dbReference type="DOI" id="10.1126/science.1196284"/>
</citation>
<scope>INVOLVEMENT IN ACNINV3</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43 AND SER-367</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2011" name="Traffic" volume="12" first="330" last="348">
<title>Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation.</title>
<authorList>
<person name="Viswanathan J."/>
<person name="Haapasalo A."/>
<person name="Bottcher C."/>
<person name="Miettinen R."/>
<person name="Kurkinen K.M."/>
<person name="Lu A."/>
<person name="Thomas A."/>
<person name="Maynard C.J."/>
<person name="Romano D."/>
<person name="Hyman B.T."/>
<person name="Berezovska O."/>
<person name="Bertram L."/>
<person name="Soininen H."/>
<person name="Dantuma N.P."/>
<person name="Tanzi R.E."/>
<person name="Hiltunen M."/>
</authorList>
<dbReference type="PubMed" id="21143716"/>
<dbReference type="DOI" id="10.1111/j.1600-0854.2010.01149.x"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH UBQLN1</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43 AND SER-367</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="52">
<citation type="journal article" date="2015" name="Mol. Neurobiol." volume="52" first="1835" last="1849">
<title>G206D mutation of presenilin-1 reduces Pen2 interaction, increases Abeta42/Abeta40 ratio and elevates ER Ca(2+) accumulation.</title>
<authorList>
<person name="Chen W.T."/>
<person name="Hsieh Y.F."/>
<person name="Huang Y.J."/>
<person name="Lin C.C."/>
<person name="Lin Y.T."/>
<person name="Liu Y.C."/>
<person name="Lien C.C."/>
<person name="Cheng I.H."/>
</authorList>
<dbReference type="PubMed" id="25394380"/>
<dbReference type="DOI" id="10.1007/s12035-014-8969-1"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH APH1 AND PEN2</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 ASP-206</scope>
</reference>
<reference key="53" evidence="1">
<citation type="submission" date="2009-12" db="PDB data bank">
<title>Solution structure of presenilin-1 CTF subunit.</title>
<authorList>
<person name="Doetsch V."/>
</authorList>
</citation>
<scope>STRUCTURE BY NMR OF 292-467</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2014" name="Nature" volume="512" first="166" last="170">
<title>Three-dimensional structure of human gamma-secretase.</title>
<authorList>
<person name="Lu P."/>
<person name="Bai X.C."/>
<person name="Ma D."/>
<person name="Xie T."/>
<person name="Yan C."/>
<person name="Sun L."/>
<person name="Yang G."/>
<person name="Zhao Y."/>
<person name="Zhou R."/>
<person name="Scheres S.H."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="25043039"/>
<dbReference type="DOI" id="10.1038/nature13567"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (4.5 ANGSTROMS)</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>SUBUNIT</scope>
<scope>TOPOLOGY</scope>
</reference>
<reference key="55" evidence="4 5 6 7">
<citation type="journal article" date="2015" name="Elife" volume="4">
<title>Sampling the conformational space of the catalytic subunit of human gamma-secretase.</title>
<authorList>
<person name="Bai X.C."/>
<person name="Rajendra E."/>
<person name="Yang G."/>
<person name="Shi Y."/>
<person name="Scheres S.H."/>
</authorList>
<dbReference type="PubMed" id="26623517"/>
<dbReference type="DOI" id="10.7554/elife.11182"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (4.00 ANGSTROMS)</scope>
<scope>SUBUNIT</scope>
<scope>TOPOLOGY</scope>
</reference>
<reference key="56" evidence="3">
<citation type="journal article" date="2015" name="Nature" volume="525" first="212" last="217">
<title>An atomic structure of human gamma-secretase.</title>
<authorList>
<person name="Bai X.C."/>
<person name="Yan C."/>
<person name="Yang G."/>
<person name="Lu P."/>
<person name="Ma D."/>
<person name="Sun L."/>
<person name="Zhou R."/>
<person name="Scheres S.H."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="26280335"/>
<dbReference type="DOI" id="10.1038/nature14892"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS)</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TOPOLOGY</scope>
<scope>SUBUNIT</scope>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>CHARACTERIZATION OF VARIANTS AD3 LEU-213; ILE-237 AND PHE-261</scope>
<scope>MUTAGENESIS OF ILE-202; LEU-226; LEU-248 AND LEU-424</scope>
</reference>
<reference key="57" evidence="2">
<citation type="journal article" date="2015" name="Proc. Natl. Acad. Sci. U.S.A." volume="112" first="6003" last="6008">
<title>Structural basis of human gamma-secretase assembly.</title>
<authorList>
<person name="Sun L."/>
<person name="Zhao L."/>
<person name="Yang G."/>
<person name="Yan C."/>
<person name="Zhou R."/>
<person name="Zhou X."/>
<person name="Xie T."/>
<person name="Zhao Y."/>
<person name="Wu S."/>
<person name="Li X."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="25918421"/>
<dbReference type="DOI" id="10.1073/pnas.1506242112"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) OF 81-463</scope>
<scope>SUBUNIT</scope>
<scope>TOPOLOGY</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2019" name="Nature" volume="565" first="192" last="197">
<title>Structural basis of Notch recognition by human gamma-secretase.</title>
<authorList>
<person name="Yang G."/>
<person name="Zhou R."/>
<person name="Zhou Q."/>
<person name="Guo X."/>
<person name="Yan C."/>
<person name="Ke M."/>
<person name="Lei J."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="30598546"/>
<dbReference type="DOI" id="10.1038/s41586-018-0813-8"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (2.70 ANGSTROMS) OF MUTANT ALA-385 IN COMPLEX WITH NOTCH1; PSENEN; APH1A AND NCSTN</scope>
<scope>SUBUNIT</scope>
<scope>TOPOLOGY</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF GLN-112; 288-TYR--SER-290; 377-ARG--LEU-381; ASP-385; LEU-432 AND 432-LEU--ALA-434</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="59">
<citation type="journal article" date="2019" name="Science">
<title>Recognition of the amyloid precursor protein by human gamma-secretase.</title>
<authorList>
<person name="Zhou R."/>
<person name="Yang G."/>
<person name="Guo X."/>
<person name="Zhou Q."/>
<person name="Lei J."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="30630874"/>
<dbReference type="DOI" id="10.1126/science.aaw0930"/>
</citation>
<scope>STRUCTURE BY ELECTRON MICROSCOPY (2.60 ANGSTROMS) OF MUTANT ALA-385 IN COMPLEX WITH APP CHAIN C83; PSENEN; APH1A AND NCSTN</scope>
<scope>SUBUNIT</scope>
<scope>TOPOLOGY</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION</scope>
<scope>ACTIVE SITE</scope>
<scope>DOMAIN</scope>
<scope>MUTAGENESIS OF GLN-112; 288-TYR--SER-290; 377-ARG--LEU-381; ASP-385; LEU-432 AND 432-LEU--ALA-434</scope>
</reference>
<reference key="60">
<citation type="journal article" date="1995" name="Hum. Mol. Genet." volume="4" first="2363" last="2372">
<title>Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3.</title>
<authorList>
<person name="Cruts M."/>
<person name="Backhovens H."/>
<person name="Wang S.-Y."/>
<person name="van Gassen G."/>
<person name="Theuns J."/>
<person name="de Jonghe C."/>
<person name="Wehnert A."/>
<person name="de Voecht J."/>
<person name="de Winter G."/>
<person name="Cras P."/>
<person name="Bruyland M."/>
<person name="Datson N."/>
<person name="Weissenbach J."/>
<person name="den Dunnen J.T."/>
<person name="Martin J.-J."/>
<person name="Hendriks L."/>
<person name="Van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="8634711"/>
<dbReference type="DOI" id="10.1093/hmg/4.12.2363"/>
</citation>
<scope>VARIANTS AD3 THR-143 AND ALA-384</scope>
</reference>
<reference key="61">
<citation type="journal article" date="1995" name="Hum. Mol. Genet." volume="4" first="2373" last="2377">
<title>Mutations of the presenilin I gene in families with early-onset Alzheimer's disease.</title>
<authorList>
<person name="Campion D."/>
<person name="Flaman J.-M."/>
<person name="Brice A."/>
<person name="Hannequin D."/>
<person name="Dubois B."/>
<person name="Martin C."/>
<person name="Moreau V."/>
<person name="Charbonnier F."/>
<person name="Didierjean O."/>
<person name="Tardieu S."/>
<person name="Penet C."/>
<person name="Puel M."/>
<person name="Pasquier F."/>
<person name="le Doze F."/>
<person name="Bellis G."/>
<person name="Calenda A."/>
<person name="Heilig R."/>
<person name="Martinez M."/>
<person name="Mallet J."/>
<person name="Bellis M."/>
<person name="Clerget-Darpoux F."/>
<person name="Agid Y."/>
<person name="Frebourg T."/>
</authorList>
<dbReference type="PubMed" id="8634712"/>
<dbReference type="DOI" id="10.1093/hmg/4.12.2373"/>
</citation>
<scope>VARIANTS AD3 LEU-82; HIS-115; THR-139; ARG-163; THR-231; LEU-264; VAL-392 AND TYR-410</scope>
</reference>
<reference key="62">
<citation type="journal article" date="1995" name="Nature" volume="376" first="775" last="778">
<title>Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.</title>
<authorList>
<person name="Rogaev E.I."/>
<person name="Sherrington R."/>
<person name="Rogaeva E.A."/>
<person name="Levesque G."/>
<person name="Ikeda M."/>
<person name="Liang Y."/>
<person name="Chi H."/>
<person name="Lin C."/>
<person name="Holman K."/>
<person name="Tsuda T."/>
<person name="Mar L."/>
<person name="Sorbi S."/>
<person name="Nacmias B."/>
<person name="Piacentini S."/>
<person name="Amaducci L."/>
<person name="Chumakov I."/>
<person name="Cohen D."/>
<person name="Lannfelt L."/>
<person name="Fraser P.E."/>
<person name="Rommens J.M."/>
<person name="St George-Hyslop P.H."/>
</authorList>
<dbReference type="PubMed" id="7651536"/>
<dbReference type="DOI" id="10.1038/376775a0"/>
</citation>
<scope>VARIANTS AD3 VAL-260; VAL-285 AND VAL-392</scope>
</reference>
<reference key="63">
<citation type="journal article" date="1995" name="Nat. Genet." volume="11" first="219" last="222">
<title>The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families.</title>
<authorList>
<person name="Clark R.F."/>
<person name="Hutton M."/>
<person name="Fuldner R.A."/>
<person name="Froelich S."/>
<person name="Karran E."/>
<person name="Talbot C."/>
<person name="Crook R."/>
<person name="Lendon C.L."/>
<person name="Prihar G."/>
<person name="He C."/>
<person name="Korenblat K."/>
<person name="Martinez A."/>
<person name="Wragg M."/>
<person name="Busfield F."/>
<person name="Behrens M.I."/>
<person name="Myers A."/>
<person name="Norton J."/>
<person name="Morris J."/>
<person name="Mehta N."/>
<person name="Pearson C."/>
<person name="Lincoln S."/>
<person name="Baker M."/>
<person name="Duff K."/>
<person name="Zehr C."/>
<person name="Perez-Tur J."/>
<person name="Houlden H."/>
<person name="Ruiz A."/>
<person name="Ossa J."/>
<person name="Lopera F."/>
<person name="Arcos M."/>
<person name="Madrigal L."/>
<person name="Collinge J."/>
<person name="Humphreys C."/>
<person name="Asworth T."/>
<person name="Sarner S."/>
<person name="Fox N.C."/>
<person name="Harvey R."/>
<person name="Kennedy A."/>
<person name="Roques P.K."/>
<person name="Cline R.T."/>
<person name="Phillips C.A."/>
<person name="Venter J.C."/>
<person name="Forsel L."/>
<person name="Axelman K."/>
<person name="Lilius L."/>
<person name="Johnston J."/>
<person name="Cowburn R."/>
<person name="Viitanen M."/>
<person name="Winblad B."/>
<person name="Kosik K.S."/>
<person name="Haltia M."/>
<person name="Poyhonen M."/>
<person name="Dickson D."/>
<person name="Mann D."/>
<person name="Neary D."/>
<person name="Snowden J."/>
<person name="Lantos P."/>
<person name="Lannfelt L."/>
<person name="Rossor M.N."/>
<person name="Roberts G.W."/>
<person name="Adams M.D."/>
<person name="Hardy J."/>
<person name="Goate A.M."/>
</authorList>
<dbReference type="PubMed" id="7550356"/>
<dbReference type="DOI" id="10.1038/ng1095-219"/>
</citation>
<scope>VARIANTS AD3 VAL-139; VAL-146; TYR-163; THR-267; ALA-280 AND GLY-280</scope>
</reference>
<reference key="64">
<citation type="journal article" date="1996" name="Nat. Med." volume="2" first="1146" last="1150">
<title>The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.</title>
<authorList>
<person name="Lemere C.A."/>
<person name="Lopera F."/>
<person name="Kosik K.S."/>
<person name="Lendon C.L."/>
<person name="Ossa J."/>
<person name="Saido T.C."/>
<person name="Yamaguchi H."/>
<person name="Ruiz A."/>
<person name="Martinez A."/>
<person name="Madrigal L."/>
<person name="Hincapie L."/>
<person name="Arango J.C."/>
<person name="Anthony D.C."/>
<person name="Koo E.H."/>
<person name="Goate A.M."/>
<person name="Selkoe D.J."/>
<person name="Arango J.C."/>
</authorList>
<dbReference type="PubMed" id="8837617"/>
<dbReference type="DOI" id="10.1038/nm1096-1146"/>
</citation>
<scope>VARIANT AD3 ALA-280</scope>
<scope>INVOLVEMENT IN AD3</scope>
</reference>
<reference key="65">
<citation type="journal article" date="1996" name="Neurosci. Lett." volume="208" first="195" last="198">
<title>Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families.</title>
<authorList>
<person name="Kamino K."/>
<person name="Sato S."/>
<person name="Sakaki Y."/>
<person name="Yoshiiwa A."/>
<person name="Nishiwaki Y."/>
<person name="Takeda H."/>
<person name="Tanabe H."/>
<person name="Nishimura T."/>
<person name="Li K."/>
<person name="St George-Hyslop P.H."/>
<person name="Miki T."/>
<person name="Ogihara T."/>
</authorList>
<dbReference type="PubMed" id="8733303"/>
<dbReference type="DOI" id="10.1016/0304-3940(96)12587-8"/>
</citation>
<scope>VARIANTS AD3 PHE-96; ARG-163 AND THR-213</scope>
</reference>
<reference key="66">
<citation type="journal article" date="1997" name="Ann. Neurol." volume="42" first="124" last="128">
<title>Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation.</title>
<authorList>
<person name="Crook R."/>
<person name="Ellis R."/>
<person name="Shanks M."/>
<person name="Thal L.J."/>
<person name="Perez-Tur J."/>
<person name="Baker M."/>
<person name="Hutton M."/>
<person name="Haltia T."/>
<person name="Hardy J."/>
<person name="Galasko D."/>
</authorList>
<dbReference type="PubMed" id="9225696"/>
<dbReference type="DOI" id="10.1002/ana.410420121"/>
</citation>
<scope>VARIANT AD3 ASP-135</scope>
</reference>
<reference key="67">
<citation type="journal article" date="1997" name="Hum. Mutat." volume="10" first="186" last="195">
<title>E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles.</title>
<authorList>
<person name="Lendon C.L."/>
<person name="Martinez A."/>
<person name="Behrens I.M."/>
<person name="Kosik K.S."/>
<person name="Madrigal L."/>
<person name="Norton J."/>
<person name="Neuman R."/>
<person name="Myers A."/>
<person name="Busfield F."/>
<person name="Wragg M."/>
<person name="Arcos M."/>
<person name="Arango-Viana J.C."/>
<person name="Ossa J."/>
<person name="Ruiz A."/>
<person name="Goate A.M."/>
<person name="Lopera F."/>
</authorList>
<dbReference type="PubMed" id="9298817"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1997)10:3&lt;186::aid-humu2&gt;3.0.co;2-h"/>
</citation>
<scope>VARIANT AD3 ALA-280</scope>
</reference>
<reference key="68">
<citation type="journal article" date="1997" name="NeuroReport" volume="8" first="1537" last="1542">
<title>Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.</title>
<authorList>
<person name="Kwok J.B.J."/>
<person name="Taddei K."/>
<person name="Hallupp M."/>
<person name="Fisher C."/>
<person name="Brooks W.S."/>
<person name="Broe G.A."/>
<person name="Hardy J."/>
<person name="Fulham M.J."/>
<person name="Nicholson G.A."/>
<person name="Stell R."/>
<person name="St George-Hyslop P.H."/>
<person name="Fraser P.E."/>
<person name="Kakulas B."/>
<person name="Clarnette R."/>
<person name="Relkin N."/>
<person name="Gandy S.E."/>
<person name="Schofield P.R."/>
<person name="Martins R.N."/>
</authorList>
<dbReference type="PubMed" id="9172170"/>
<dbReference type="DOI" id="10.1097/00001756-199704140-00043"/>
</citation>
<scope>VARIANTS AD3 THR-233 AND THR-278</scope>
</reference>
<reference key="69">
<citation type="journal article" date="1998" name="Ann. Genet." volume="41" first="149" last="153">
<title>A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease.</title>
<authorList>
<person name="Ramirez-Duenas M.G."/>
<person name="Rogaeva E.A."/>
<person name="Leal C.A."/>
<person name="Lin C."/>
<person name="Ramirez-Casillas G.A."/>
<person name="Hernandez-Romo J.A."/>
<person name="St George-Hyslop P.H."/>
<person name="Cantu J.M."/>
</authorList>
<dbReference type="PubMed" id="9833068"/>
</citation>
<scope>VARIANT AD3 PRO-171</scope>
</reference>
<reference key="70">
<citation type="journal article" date="1998" name="Ann. Neurol." volume="44" first="965" last="967">
<title>The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease.</title>
<authorList>
<person name="Mattila K.M."/>
<person name="Forsell C."/>
<person name="Pirttila T."/>
<person name="Rinne J.O."/>
<person name="Lehtimaki T."/>
<person name="Roytta M."/>
<person name="Lilius L."/>
<person name="Eerola A."/>
<person name="St George-Hyslop P.H."/>
<person name="Frey H."/>
<person name="Lannfelt L."/>
</authorList>
<dbReference type="PubMed" id="9851443"/>
<dbReference type="DOI" id="10.1002/ana.410440617"/>
</citation>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="71">
<citation type="journal article" date="1998" name="Ann. Neurol." volume="44" first="985" last="986">
<title>Missense mutation E318G of the presenilin-1 gene appears to be a nonpathogenic polymorphism.</title>
<authorList>
<person name="Aldudo J."/>
<person name="Bullido M.J."/>
<person name="Frank A."/>
<person name="Valdivieso F."/>
</authorList>
<dbReference type="PubMed" id="9851450"/>
<dbReference type="DOI" id="10.1002/ana.410440624"/>
</citation>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="72">
<citation type="journal article" date="1998" name="Hum. Mol. Genet." volume="7" first="43" last="51">
<title>Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease.</title>
<authorList>
<person name="Cruts M."/>
<person name="van Duijn C.M."/>
<person name="Backhovens H."/>
<person name="van den Broeck M."/>
<person name="Wehnert A."/>
<person name="Serneels S."/>
<person name="Sherrington R."/>
<person name="Hutton M."/>
<person name="Hardy J."/>
<person name="St George-Hyslop P.H."/>
<person name="Hofman A."/>
<person name="van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="9384602"/>
<dbReference type="DOI" id="10.1093/hmg/7.1.43"/>
</citation>
<scope>VARIANTS AD3 VAL-79; CYS-115 AND VAL-231</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="73">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="11" first="216" last="221">
<title>Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene.</title>
<authorList>
<person name="Poorkaj P."/>
<person name="Sharma V."/>
<person name="Anderson L."/>
<person name="Nemens E."/>
<person name="Alonso M.E."/>
<person name="Orr H."/>
<person name="White J."/>
<person name="Heston L."/>
<person name="Bird T.D."/>
<person name="Schellenberg G.D."/>
</authorList>
<dbReference type="PubMed" id="9521423"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1998)11:3&lt;216::aid-humu6&gt;3.0.co;2-f"/>
</citation>
<scope>VARIANTS AD3 ASP-120; ARG-163; VAL-209; VAL-260; LEU-264; TYR-410 AND PRO-426</scope>
</reference>
<reference key="74">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="11" first="481" last="481">
<title>Missense mutation in exon 11 (codon 378) of the presenilin-1 gene in a French family with early-onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification.</title>
<authorList>
<person name="Besancon R."/>
<person name="Lorenzi A."/>
<person name="Cruts M."/>
<person name="Radawiec S."/>
<person name="Sturtz F."/>
<person name="Broussolle E."/>
<person name="Chazot G."/>
<person name="van Broeckhoven C."/>
<person name="Chamba G."/>
<person name="Vandenberghe A."/>
</authorList>
<dbReference type="PubMed" id="10200054"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1998)11:6&lt;481::aid-humu13&gt;3.0.co;2-n"/>
</citation>
<scope>VARIANT AD3 GLU-378</scope>
</reference>
<reference key="75">
<citation type="journal article" date="1998" name="J. Med. Genet." volume="35" first="672" last="673">
<title>De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases.</title>
<authorList>
<person name="Dumanchin C."/>
<person name="Brice A."/>
<person name="Campion D."/>
<person name="Hannequin D."/>
<person name="Martin C."/>
<person name="Moreau V."/>
<person name="Agid Y."/>
<person name="Martinez M."/>
<person name="Clerget-Darpoux F."/>
<person name="Frebourg T."/>
</authorList>
<dbReference type="PubMed" id="9719376"/>
<dbReference type="DOI" id="10.1136/jmg.35.8.672"/>
</citation>
<scope>VARIANT AD3 LYS-139</scope>
</reference>
<reference key="76">
<citation type="journal article" date="1998" name="NeuroReport" volume="9" first="217" last="221">
<title>A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years.</title>
<authorList>
<person name="Wisniewski T."/>
<person name="Dowjat W.K."/>
<person name="Buxbaum J.D."/>
<person name="Khorkova O."/>
<person name="Efthimiopoulos S."/>
<person name="Kulczycki J."/>
<person name="Lojkowska W."/>
<person name="Wegiel J."/>
<person name="Wisniewski H.M."/>
<person name="Frangione B."/>
</authorList>
<dbReference type="PubMed" id="9507958"/>
<dbReference type="DOI" id="10.1097/00001756-199801260-00008"/>
</citation>
<scope>VARIANT AD3 LEU-117</scope>
</reference>
<reference key="77">
<citation type="journal article" date="1998" name="NeuroReport" volume="9" first="3335" last="3339">
<title>Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease.</title>
<authorList>
<person name="Taddei K."/>
<person name="Kwok J.B."/>
<person name="Kril J.J."/>
<person name="Halliday G.M."/>
<person name="Creasey H."/>
<person name="Hallupp M."/>
<person name="Fisher C."/>
<person name="Brooks W.S."/>
<person name="Chung C."/>
<person name="Andrews C."/>
<person name="Masters C.L."/>
<person name="Schofield P.R."/>
<person name="Martins R.N."/>
</authorList>
<dbReference type="PubMed" id="9831473"/>
<dbReference type="DOI" id="10.1097/00001756-199810050-00034"/>
</citation>
<scope>VARIANTS AD3 LEU-169 AND GLN-436</scope>
</reference>
<reference key="78">
<citation type="journal article" date="1999" name="Am. J. Hum. Genet." volume="64" first="290" last="292">
<title>The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease.</title>
<authorList>
<person name="Dermaut B."/>
<person name="Cruts M."/>
<person name="Slooter A.J.C."/>
<person name="van Gestel S."/>
<person name="de Jonghe C."/>
<person name="Vanderstichele H."/>
<person name="Vanmechelen E."/>
<person name="Breteler M.M."/>
<person name="Hofman A."/>
<person name="van Duijn C.M."/>
<person name="van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="9915968"/>
<dbReference type="DOI" id="10.1086/302200"/>
</citation>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="79">
<citation type="journal article" date="1999" name="Am. J. Hum. Genet." volume="65" first="664" last="670">
<title>Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.</title>
<authorList>
<person name="Campion D."/>
<person name="Dumanchin C."/>
<person name="Hannequin D."/>
<person name="Dubois B."/>
<person name="Belliard S."/>
<person name="Puel M."/>
<person name="Thomas-Anterion C."/>
<person name="Michon A."/>
<person name="Martin C."/>
<person name="Charbonnier F."/>
<person name="Raux G."/>
<person name="Camuzat A."/>
<person name="Penet C."/>
<person name="Mesnage V."/>
<person name="Martinez M."/>
<person name="Clerget-Darpoux F."/>
<person name="Brice A."/>
<person name="Frebourg T."/>
</authorList>
<dbReference type="PubMed" id="10441572"/>
<dbReference type="DOI" id="10.1086/302553"/>
</citation>
<scope>VARIANTS AD3 LEU-82; HIS-115; ASP-120; THR-139; LEU-146; ILE-147; ARG-163; CYS-165; TRP-173; THR-231; THR-233; PRO-235; LEU-264; ILE-390; VAL-392 AND TYR-410</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="80">
<citation type="journal article" date="1999" name="Hum. Mutat." volume="13" first="256" last="256">
<title>Pathogenic presenilin 1 mutations (P436S and I143F) in early-onset Alzheimer's disease in the UK.</title>
<authorList>
<person name="Palmer M.S."/>
<person name="Beck J.A."/>
<person name="Campbell T.A."/>
<person name="Humphries C.B."/>
<person name="Roques P.K."/>
<person name="Fox N.C."/>
<person name="Harvey R."/>
<person name="Rossor M.N."/>
<person name="Collinge J."/>
</authorList>
<dbReference type="PubMed" id="10090481"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1999)13:3&lt;256::aid-humu11&gt;3.0.co;2-p"/>
</citation>
<scope>VARIANTS AD3 PHE-143 AND SER-436</scope>
</reference>
<reference key="81">
<citation type="journal article" date="1999" name="Hum. Mutat." volume="14" first="90" last="90">
<title>A novel missense mutation (G209R) in exon 8 of the presenilin 1 gene in a Japanese family with presenile familial Alzheimer's disease.</title>
<authorList>
<person name="Sugiyama N."/>
<person name="Suzuki K."/>
<person name="Matsumura T."/>
<person name="Kawanishi C."/>
<person name="Onishi H."/>
<person name="Yamada Y."/>
<person name="Iseki E."/>
<person name="Kosaka K."/>
</authorList>
<dbReference type="PubMed" id="10447269"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(1999)14:1&lt;90::aid-humu19&gt;3.0.co;2-s"/>
</citation>
<scope>VARIANT AD3 ARG-209</scope>
</reference>
<reference key="82">
<citation type="journal article" date="1999" name="Hum. Mutat." volume="14" first="433" last="439">
<title>DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: two novel mutations.</title>
<authorList>
<person name="Aldudo J."/>
<person name="Bullido M.J."/>
<person name="Valdivieso F."/>
</authorList>
<dbReference type="PubMed" id="10533070"/>
<dbReference type="DOI" id="10.1002/(sici)1098-1004(199911)14:5&lt;433::aid-humu10&gt;3.0.co;2-k"/>
</citation>
<scope>VARIANTS AD3 LEU-233; ARG-282 AND THR-409</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="83">
<citation type="journal article" date="1999" name="Neurology" volume="52" first="566" last="570">
<title>A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures.</title>
<authorList>
<person name="Ezquerra M."/>
<person name="Carnero C."/>
<person name="Blesa R."/>
<person name="Gelpi J.L."/>
<person name="Ballesta F."/>
<person name="Oliva R."/>
</authorList>
<dbReference type="PubMed" id="10025789"/>
<dbReference type="DOI" id="10.1212/wnl.52.3.566"/>
</citation>
<scope>VARIANT AD3 PRO-169</scope>
</reference>
<reference key="84">
<citation type="journal article" date="1999" name="NeuroReport" volume="10" first="503" last="507">
<title>Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene.</title>
<authorList>
<person name="Smith M.J."/>
<person name="Gardner R.J."/>
<person name="Knight M.A."/>
<person name="Forrest S.M."/>
<person name="Beyreuther K."/>
<person name="Storey E."/>
<person name="McLean C.A."/>
<person name="Cotton R.G."/>
<person name="Cappal R."/>
<person name="Masters C.L."/>
</authorList>
<dbReference type="PubMed" id="10208579"/>
<dbReference type="DOI" id="10.1097/00001756-199902250-00011"/>
</citation>
<scope>VARIANT AD3 PRO-219</scope>
</reference>
<reference key="85">
<citation type="journal article" date="1999" name="NeuroReport" volume="10" first="2255" last="2260">
<title>A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease.</title>
<authorList>
<person name="Romero I."/>
<person name="Joergensen P."/>
<person name="Bolwig G."/>
<person name="Fraser P.E."/>
<person name="Rogaeva E."/>
<person name="Mann D."/>
<person name="Havsager A.-M."/>
<person name="Joergensen A.L."/>
</authorList>
<dbReference type="PubMed" id="10439444"/>
<dbReference type="DOI" id="10.1097/00001756-199908020-00006"/>
</citation>
<scope>VARIANT AD3 ASN-116</scope>
</reference>
<reference key="86">
<citation type="journal article" date="2000" name="Am. J. Hum. Genet." volume="66" first="110" last="117">
<title>High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.</title>
<authorList>
<person name="Finckh U."/>
<person name="Mueller-Thomsen T."/>
<person name="Mann U."/>
<person name="Eggers C."/>
<person name="Marksteiner J."/>
<person name="Meins W."/>
<person name="Binetti G."/>
<person name="Alberici A."/>
<person name="Hock C."/>
<person name="Nitsch R.M."/>
<person name="Gal A."/>
</authorList>
<dbReference type="PubMed" id="10631141"/>
<dbReference type="DOI" id="10.1086/302702"/>
</citation>
<scope>VARIANTS AD3 VAL-79; LEU-105 AND VAL-139</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="87">
<citation type="journal article" date="2000" name="J. Neurol. Neurosurg. Psych." volume="68" first="220" last="223">
<title>Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy.</title>
<authorList>
<person name="Yasuda M."/>
<person name="Maeda S."/>
<person name="Kawamata T."/>
<person name="Tamaoka A."/>
<person name="Yamamoto Y."/>
<person name="Kuroda S."/>
<person name="Maeda K."/>
<person name="Tanaka C."/>
</authorList>
<dbReference type="PubMed" id="10644793"/>
<dbReference type="DOI" id="10.1136/jnnp.68.2.220"/>
</citation>
<scope>VARIANT AD3 SER-405</scope>
</reference>
<reference key="88">
<citation type="journal article" date="2000" name="Biochem. Biophys. Res. Commun." volume="277" first="261" last="263">
<title>The presenilin 1 C92S mutation increases abeta 42 production.</title>
<authorList>
<person name="Lewis P.A."/>
<person name="Perez-Tur J."/>
<person name="Golde T.E."/>
<person name="Hardy J."/>
</authorList>
<dbReference type="PubMed" id="11027672"/>
<dbReference type="DOI" id="10.1006/bbrc.2000.3646"/>
</citation>
<scope>VARIANT AD3 SER-92</scope>
</reference>
<reference key="89">
<citation type="journal article" date="2000" name="Neurology" volume="55" first="1577" last="1578">
<title>Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation.</title>
<authorList>
<person name="Raux G."/>
<person name="Gantier R."/>
<person name="Thomas-Anterion C."/>
<person name="Boulliat J."/>
<person name="Verpillat P."/>
<person name="Hannequin D."/>
<person name="Brice A."/>
<person name="Frebourg T."/>
<person name="Campion D."/>
</authorList>
<dbReference type="PubMed" id="11094121"/>
<dbReference type="DOI" id="10.1212/wnl.55.10.1577"/>
</citation>
<scope>VARIANT FRONTOTEMPORAL DEMENTIA PRO-113</scope>
</reference>
<reference key="90">
<citation type="journal article" date="2001" name="Am. J. Med. Genet." volume="103" first="138" last="143">
<title>Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia.</title>
<authorList>
<person name="Arango D."/>
<person name="Cruts M."/>
<person name="Torres O."/>
<person name="Backhovens H."/>
<person name="Serrano M.L."/>
<person name="Villareal E."/>
<person name="Montanes P."/>
<person name="Matallana D."/>
<person name="Cano C."/>
<person name="Van Broeckhoven C."/>
<person name="Jacquier M."/>
</authorList>
<dbReference type="PubMed" id="11568920"/>
<dbReference type="DOI" id="10.1002/1096-8628(20011001)103:2&lt;138::aid-ajmg1529&gt;3.0.co;2-8"/>
</citation>
<scope>VARIANTS AD3 MET-94; THR-143 AND ALA-280</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="91">
<citation type="journal article" date="2001" name="Brain" volume="124" first="2383" last="2392">
<title>Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation.</title>
<authorList>
<person name="Dermaut B."/>
<person name="Kumar-Singh S."/>
<person name="De Jonghe C."/>
<person name="Cruts M."/>
<person name="Loefgren A."/>
<person name="Luebke U."/>
<person name="Cras P."/>
<person name="Dom R."/>
<person name="De Deyn P.P."/>
<person name="Martin J.J."/>
<person name="Van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="11701593"/>
<dbReference type="DOI" id="10.1093/brain/124.12.2383"/>
</citation>
<scope>VARIANT AD3 VAL-282</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 VAL-282</scope>
</reference>
<reference key="92">
<citation type="journal article" date="2001" name="Hum. Genet." volume="109" first="242" last="242">
<authorList>
<person name="Ringman J.M."/>
<person name="Jain V."/>
<person name="Murrell J."/>
<person name="Ghetti B."/>
<person name="Cochran E.J."/>
</authorList>
</citation>
<scope>ERRATUM OF PUBMED:11701593</scope>
<scope>VARIANT AD3 GLU-431</scope>
</reference>
<reference key="93">
<citation type="journal article" date="2001" name="JAMA" volume="286" first="2257" last="2263">
<title>A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families.</title>
<authorList>
<person name="Athan E.S."/>
<person name="Williamson J."/>
<person name="Ciappa A."/>
<person name="Santana V."/>
<person name="Romas S.N."/>
<person name="Lee J.H."/>
<person name="Rondon H."/>
<person name="Lantigua R.A."/>
<person name="Medrano M."/>
<person name="Torres M."/>
<person name="Arawaka S."/>
<person name="Rogaeva E."/>
<person name="Song Y.-Q."/>
<person name="Sato C."/>
<person name="Kawarai T."/>
<person name="Fafel K.C."/>
<person name="Boss M.A."/>
<person name="Seltzer W.K."/>
<person name="Stern Y."/>
<person name="St George-Hyslop P.H."/>
<person name="Tycko B."/>
<person name="Mayeux R."/>
</authorList>
<dbReference type="PubMed" id="11710891"/>
<dbReference type="DOI" id="10.1001/jama.286.18.2257"/>
</citation>
<scope>VARIANT AD3 ALA-206</scope>
</reference>
<reference key="94">
<citation type="journal article" date="2001" name="J. Neurol. Neurosurg. Psych." volume="71" first="556" last="557">
<title>Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile).</title>
<authorList>
<person name="Sodeyama N."/>
<person name="Iwata T."/>
<person name="Ishikawa K."/>
<person name="Mizusawa H."/>
<person name="Yamada M."/>
<person name="Itoh Y."/>
<person name="Otomo E."/>
<person name="Matsushita M."/>
<person name="Komatsuzaki Y."/>
</authorList>
<dbReference type="PubMed" id="11561050"/>
<dbReference type="DOI" id="10.1136/jnnp.71.4.556"/>
</citation>
<scope>VARIANT AD3 ILE-237</scope>
</reference>
<reference key="95">
<citation type="journal article" date="2001" name="Neurology" volume="57" first="621" last="625">
<title>Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.</title>
<authorList>
<person name="Rogaeva E.A."/>
<person name="Fafel K.C."/>
<person name="Song Y.Q."/>
<person name="Medeiros H."/>
<person name="Sato C."/>
<person name="Liang Y."/>
<person name="Richard E."/>
<person name="Rogaev E.I."/>
<person name="Frommelt P."/>
<person name="Sadovnick A.D."/>
<person name="Meschino W."/>
<person name="Rockwood K."/>
<person name="Boss M.A."/>
<person name="Mayeux R."/>
<person name="St George-Hyslop P."/>
</authorList>
<dbReference type="PubMed" id="11524469"/>
<dbReference type="DOI" id="10.1212/wnl.57.4.621"/>
</citation>
<scope>VARIANTS AD3 GLN-35; VAL-79; CYS-115; ASN-116; THR-143; ILE-146; LEU-146; VAL-146; TYR-156 DELINS PHE-THR-TYR; ARG-163; LEU-177; SER-177; PRO-178; ALA-206; SER-206; GLU-209; LEU-213; ARG-222; THR-231; LEU-233; PRO-235; PHE-261; ARG-274; ARG-352 INS; ILE-354; GLN-358; TYR-365; VAL-394; PHE-418; GLU-431; PHE-435 AND VAL-439</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="96">
<citation type="journal article" date="2002" name="Am. J. Med. Genet." volume="114" first="292" last="298">
<title>Molecular evidence of presenilin 1 mutation in familial early onset dementia.</title>
<authorList>
<person name="Matsubara-Tsutsui M."/>
<person name="Yasuda M."/>
<person name="Yamagata H."/>
<person name="Nomura T."/>
<person name="Taguchi K."/>
<person name="Kohara K."/>
<person name="Miyoshi K."/>
<person name="Miki T."/>
</authorList>
<dbReference type="PubMed" id="11920851"/>
<dbReference type="DOI" id="10.1002/ajmg.10250"/>
</citation>
<scope>VARIANT AD3 SER-266</scope>
</reference>
<reference key="97">
<citation type="journal article" date="2002" name="J. Neurol. Neurosurg. Psych." volume="72" first="266" last="269">
<title>A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances.</title>
<authorList>
<person name="Queralt R."/>
<person name="Ezquerra M."/>
<person name="Lleo A."/>
<person name="Castellvi M."/>
<person name="Gelpi J."/>
<person name="Ferrer I."/>
<person name="Acarin N."/>
<person name="Pasarin L."/>
<person name="Blesa R."/>
<person name="Oliva R."/>
</authorList>
<dbReference type="PubMed" id="11796781"/>
<dbReference type="DOI" id="10.1136/jnnp.72.2.266"/>
</citation>
<scope>VARIANT AD3 LEU-89</scope>
</reference>
<reference key="98">
<citation type="journal article" date="2002" name="Neurology" volume="59" first="1108" last="1110">
<title>Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.</title>
<authorList>
<person name="O'Riordan S."/>
<person name="McMonagle P."/>
<person name="Janssen J.C."/>
<person name="Fox N.C."/>
<person name="Farrell M."/>
<person name="Collinge J."/>
<person name="Rossor M.N."/>
<person name="Hutchinson M."/>
</authorList>
<dbReference type="PubMed" id="12370477"/>
<dbReference type="DOI" id="10.1212/wnl.59.7.1108"/>
</citation>
<scope>VARIANT AD3 GLY-280</scope>
</reference>
<reference key="99">
<citation type="journal article" date="2002" name="Proc. Natl. Acad. Sci. U.S.A." volume="99" first="8025" last="8030">
<title>Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production.</title>
<authorList>
<person name="Moehlmann T."/>
<person name="Winkler E."/>
<person name="Xia X."/>
<person name="Edbauer D."/>
<person name="Murrell J."/>
<person name="Capell A."/>
<person name="Kaether C."/>
<person name="Zheng H."/>
<person name="Ghetti B."/>
<person name="Haass C."/>
<person name="Steiner H."/>
</authorList>
<dbReference type="PubMed" id="12048239"/>
<dbReference type="DOI" id="10.1073/pnas.112686799"/>
</citation>
<scope>VARIANT AD3 PRO-166</scope>
</reference>
<reference key="100">
<citation type="journal article" date="2002" name="Neurogenetics" volume="4" first="97" last="104">
<title>A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease.</title>
<authorList>
<person name="Bertoli-Avella A.M."/>
<person name="Marcheco Teruel B."/>
<person name="Llibre Rodriguez J.J."/>
<person name="Gomez Viera N."/>
<person name="Borrajero-Martinez I."/>
<person name="Severijnen E.A."/>
<person name="Joosse M."/>
<person name="van Duijn C.M."/>
<person name="Heredero Baute L."/>
<person name="Heutink P."/>
</authorList>
<dbReference type="PubMed" id="12484344"/>
<dbReference type="DOI" id="10.1007/s10048-002-0136-6"/>
</citation>
<scope>VARIANT AD3 MET-174</scope>
</reference>
<reference key="101">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="6748" last="6754">
<title>Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy.</title>
<authorList>
<person name="Kwok J.B.J."/>
<person name="Halliday G.M."/>
<person name="Brooks W.S."/>
<person name="Dolios G."/>
<person name="Laudon H."/>
<person name="Murayama O."/>
<person name="Hallupp M."/>
<person name="Badenhop R.F."/>
<person name="Vickers J."/>
<person name="Wang R."/>
<person name="Naslund J."/>
<person name="Takashima A."/>
<person name="Gandy S.E."/>
<person name="Schofield P.R."/>
</authorList>
<dbReference type="PubMed" id="12493737"/>
<dbReference type="DOI" id="10.1074/jbc.m211827200"/>
</citation>
<scope>VARIANT AD3 VAL-271</scope>
</reference>
<reference key="102">
<citation type="journal article" date="2003" name="Neurology" volume="60" first="235" last="239">
<title>Early onset familial Alzheimer's disease: Mutation frequency in 31 families.</title>
<authorList>
<person name="Janssen J.C."/>
<person name="Beck J.A."/>
<person name="Campbell T.A."/>
<person name="Dickinson A."/>
<person name="Fox N.C."/>
<person name="Harvey R.J."/>
<person name="Houlden H."/>
<person name="Rossor M.N."/>
<person name="Collinge J."/>
</authorList>
<dbReference type="PubMed" id="12552037"/>
<dbReference type="DOI" id="10.1212/01.wnl.0000042088.22694.e3"/>
</citation>
<scope>VARIANTS AD3 CYS-115; ILE-146; VAL-153; CYS-154; ILE-168 DEL; PRO-171; ASP-184; PHE-229; VAL-235; LEU-237; VAL-260; PHE-263; HIS-269; MET-377 AND VAL-378</scope>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="103">
<citation type="journal article" date="2004" name="Ann. Neurol." volume="55" first="617" last="626">
<title>A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.</title>
<authorList>
<person name="Dermaut B."/>
<person name="Kumar-Singh S."/>
<person name="Engelborghs S."/>
<person name="Theuns J."/>
<person name="Rademakers R."/>
<person name="Saerens J."/>
<person name="Pickut B.A."/>
<person name="Peeters K."/>
<person name="van den Broeck M."/>
<person name="Vennekens K."/>
<person name="Claes S."/>
<person name="Cruts M."/>
<person name="Cras P."/>
<person name="Martin J.J."/>
<person name="Van Broeckhoven C."/>
<person name="De Deyn P.P."/>
</authorList>
<dbReference type="PubMed" id="15122701"/>
<dbReference type="DOI" id="10.1002/ana.20083"/>
</citation>
<scope>VARIANT PIDB VAL-183</scope>
<scope>CHARACTERIZATION OF VARIANTS AD3 THR-143 AND VAL-282</scope>
<scope>CHARACTERIZATION OF VARIANT PIDB VAL-183</scope>
</reference>
<reference key="104">
<citation type="journal article" date="2004" name="Arch. Neurol." volume="61" first="1773" last="1776">
<title>A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis.</title>
<authorList>
<person name="Ataka S."/>
<person name="Tomiyama T."/>
<person name="Takuma H."/>
<person name="Yamashita T."/>
<person name="Shimada H."/>
<person name="Tsutada T."/>
<person name="Kawabata K."/>
<person name="Mori H."/>
<person name="Miki T."/>
</authorList>
<dbReference type="PubMed" id="15534188"/>
<dbReference type="DOI" id="10.1001/archneur.61.11.1773"/>
</citation>
<scope>VARIANT AD3 PRO-85</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 PRO-85</scope>
</reference>
<reference key="105">
<citation type="journal article" date="2004" name="Neurology" volume="63" first="1702" last="1704">
<title>A presenilin 1 R278I mutation presenting with language impairment.</title>
<authorList>
<person name="Godbolt A.K."/>
<person name="Beck J.A."/>
<person name="Collinge J."/>
<person name="Garrard P."/>
<person name="Warren J.D."/>
<person name="Fox N.C."/>
<person name="Rossor M.N."/>
</authorList>
<dbReference type="PubMed" id="15534260"/>
<dbReference type="DOI" id="10.1212/01.wnl.0000143060.98164.1a"/>
</citation>
<scope>VARIANT AD3 ILE-278</scope>
</reference>
<reference key="106">
<citation type="journal article" date="2004" name="Neurosci. Lett." volume="368" first="319" last="322">
<title>A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis.</title>
<authorList>
<person name="Hattori S."/>
<person name="Sakuma K."/>
<person name="Wakutani Y."/>
<person name="Wada K."/>
<person name="Shimoda M."/>
<person name="Urakami K."/>
<person name="Kowa H."/>
<person name="Nakashima K."/>
</authorList>
<dbReference type="PubMed" id="15364419"/>
<dbReference type="DOI" id="10.1016/j.neulet.2004.07.057"/>
</citation>
<scope>VARIANT AD3 ASN-154</scope>
</reference>
<reference key="107">
<citation type="journal article" date="2005" name="Arch. Neurol." volume="62" first="1821" last="1830">
<title>Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life.</title>
<authorList>
<person name="Snider B.J."/>
<person name="Norton J."/>
<person name="Coats M.A."/>
<person name="Chakraverty S."/>
<person name="Hou C.E."/>
<person name="Jervis R."/>
<person name="Lendon C.L."/>
<person name="Goate A.M."/>
<person name="McKeel D.W. Jr."/>
<person name="Morris J.C."/>
</authorList>
<dbReference type="PubMed" id="16344340"/>
<dbReference type="DOI" id="10.1001/archneur.62.12.1821"/>
</citation>
<scope>VARIANT AD3 PHE-170</scope>
</reference>
<reference key="108">
<citation type="journal article" date="2005" name="J. Alzheimers Dis." volume="7" first="119" last="124">
<title>One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer's disease.</title>
<authorList>
<person name="Jia J."/>
<person name="Xu E."/>
<person name="Shao Y."/>
<person name="Jia J."/>
<person name="Sun Y."/>
<person name="Li D."/>
</authorList>
<dbReference type="PubMed" id="15851849"/>
<dbReference type="DOI" id="10.3233/jad-2005-7204"/>
</citation>
<scope>VARIANT AD3 LEU-97</scope>
</reference>
<reference key="109">
<citation type="journal article" date="2006" name="Am. J. Hum. Genet." volume="79" first="1030" last="1039">
<title>Mutations of presenilin genes in dilated cardiomyopathy and heart failure.</title>
<authorList>
<person name="Li D."/>
<person name="Parks S.B."/>
<person name="Kushner J.D."/>
<person name="Nauman D."/>
<person name="Burgess D."/>
<person name="Ludwigsen S."/>
<person name="Partain J."/>
<person name="Nixon R.R."/>
<person name="Allen C.N."/>
<person name="Irwin R.P."/>
<person name="Jakobs P.M."/>
<person name="Litt M."/>
<person name="Hershberger R.E."/>
</authorList>
<dbReference type="PubMed" id="17186461"/>
<dbReference type="DOI" id="10.1086/509900"/>
</citation>
<scope>VARIANT CMD1U GLY-333</scope>
</reference>
<reference key="110">
<citation type="journal article" date="2006" name="Hum. Mutat." volume="27" first="686" last="695">
<title>Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.</title>
<authorList>
<person name="Kumar-Singh S."/>
<person name="Theuns J."/>
<person name="Van Broeck B."/>
<person name="Pirici D."/>
<person name="Vennekens K."/>
<person name="Corsmit E."/>
<person name="Cruts M."/>
<person name="Dermaut B."/>
<person name="Wang R."/>
<person name="Van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="16752394"/>
<dbReference type="DOI" id="10.1002/humu.20336"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 VAL-79; THR-143; VAL-231; PHE-262; PHE-263; VAL-282 AND ALA-384</scope>
</reference>
<reference key="111">
<citation type="journal article" date="2006" name="Neurogenetics" volume="7" first="195" last="200">
<title>Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families.</title>
<authorList>
<person name="Yescas P."/>
<person name="Huertas-Vazquez A."/>
<person name="Villarreal-Molina M.T."/>
<person name="Rasmussen A."/>
<person name="Tusie-Luna M.T."/>
<person name="Lopez M."/>
<person name="Canizales-Quinteros S."/>
<person name="Alonso M.E."/>
</authorList>
<dbReference type="PubMed" id="16628450"/>
<dbReference type="DOI" id="10.1007/s10048-006-0043-3"/>
</citation>
<scope>VARIANT AD3 GLU-431</scope>
</reference>
<reference key="112">
<citation type="journal article" date="2006" name="Neurogenetics" volume="7" first="277" last="279">
<title>The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families.</title>
<authorList>
<person name="Murrell J."/>
<person name="Ghetti B."/>
<person name="Cochran E."/>
<person name="Macias-Islas M.A."/>
<person name="Medina L."/>
<person name="Varpetian A."/>
<person name="Cummings J.L."/>
<person name="Mendez M.F."/>
<person name="Kawas C."/>
<person name="Chui H."/>
<person name="Ringman J.M."/>
</authorList>
<dbReference type="PubMed" id="16897084"/>
<dbReference type="DOI" id="10.1007/s10048-006-0053-1"/>
</citation>
<scope>VARIANT AD3 GLU-431</scope>
</reference>
<reference key="113">
<citation type="journal article" date="2007" name="Ann. Neurol." volume="61" first="446" last="453">
<title>Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.</title>
<authorList>
<person name="Kauwe J.S."/>
<person name="Jacquart S."/>
<person name="Chakraverty S."/>
<person name="Wang J."/>
<person name="Mayo K."/>
<person name="Fagan A.M."/>
<person name="Holtzman D.M."/>
<person name="Morris J.C."/>
<person name="Goate A.M."/>
</authorList>
<dbReference type="PubMed" id="17366635"/>
<dbReference type="DOI" id="10.1002/ana.21099"/>
</citation>
<scope>VARIANT AD3 VAL-79</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 VAL-79</scope>
</reference>
<reference key="114">
<citation type="journal article" date="2007" name="Arch. Neurol." volume="64" first="738" last="745">
<title>Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.</title>
<authorList>
<person name="Piccini A."/>
<person name="Zanusso G."/>
<person name="Borghi R."/>
<person name="Noviello C."/>
<person name="Monaco S."/>
<person name="Russo R."/>
<person name="Damonte G."/>
<person name="Armirotti A."/>
<person name="Gelati M."/>
<person name="Giordano R."/>
<person name="Zambenedetti P."/>
<person name="Russo C."/>
<person name="Ghetti B."/>
<person name="Tabaton M."/>
</authorList>
<dbReference type="PubMed" id="17502474"/>
<dbReference type="DOI" id="10.1001/archneur.64.5.738"/>
</citation>
<scope>VARIANT AD3 PHE-170</scope>
</reference>
<reference key="115">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="16155" last="16163">
<title>Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor.</title>
<authorList>
<person name="Litterst C."/>
<person name="Georgakopoulos A."/>
<person name="Shioi J."/>
<person name="Ghersi E."/>
<person name="Wisniewski T."/>
<person name="Wang R."/>
<person name="Ludwig A."/>
<person name="Robakis N.K."/>
</authorList>
<dbReference type="PubMed" id="17428795"/>
<dbReference type="DOI" id="10.1074/jbc.m611449200"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 LEU-117; LEU-146; GLU-246; VAL-260; LEU-264 AND GLY-280</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF ASP-257</scope>
</reference>
<reference key="116">
<citation type="journal article" date="2008" name="Am. J. Hum. Genet." volume="82" first="1334" last="1341">
<title>Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome.</title>
<authorList>
<person name="Cornier A.S."/>
<person name="Staehling-Hampton K."/>
<person name="Delventhal K.M."/>
<person name="Saga Y."/>
<person name="Caubet J.-F."/>
<person name="Sasaki N."/>
<person name="Ellard S."/>
<person name="Young E."/>
<person name="Ramirez N."/>
<person name="Carlo S.E."/>
<person name="Torres J."/>
<person name="Emans J.B."/>
<person name="Turnpenny P.D."/>
<person name="Pourquie O."/>
</authorList>
<dbReference type="PubMed" id="18485326"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2008.04.014"/>
</citation>
<scope>VARIANT GLY-318</scope>
</reference>
<reference key="117">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="16488" last="16496">
<title>Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta.</title>
<authorList>
<person name="Shimojo M."/>
<person name="Sahara N."/>
<person name="Mizoroki T."/>
<person name="Funamoto S."/>
<person name="Morishima-Kawashima M."/>
<person name="Kudo T."/>
<person name="Takeda M."/>
<person name="Ihara Y."/>
<person name="Ichinose H."/>
<person name="Takashima A."/>
</authorList>
<dbReference type="PubMed" id="18430735"/>
<dbReference type="DOI" id="10.1074/jbc.m801279200"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT AD3 THR-213</scope>
</reference>
<reference key="118">
<citation type="journal article" date="2009" name="Am. J. Alzheimers Dis. Other Demen." volume="24" first="404" last="407">
<title>Novel PSEN1 mutation in a Bulgarian patient with very early-onset Alzheimer's disease, spastic paraparesis, and extrapyramidal signs.</title>
<authorList>
<person name="Dintchov Traykov L."/>
<person name="Mehrabian S."/>
<person name="Van den Broeck M."/>
<person name="Radoslavova Raycheva M."/>
<person name="Cruts M."/>
<person name="Kirilova Jordanova A."/>
<person name="Van Broeckhoven C."/>
</authorList>
<dbReference type="PubMed" id="19797784"/>
<dbReference type="DOI" id="10.1177/1533317509341464"/>
</citation>
<scope>VARIANT AD3 VAL-381</scope>
</reference>
<reference key="119">
<citation type="journal article" date="2009" name="Neurology" volume="73" first="480" last="482">
<title>Presenilin1 G217R mutation linked to Alzheimer disease with cotton wool plaques.</title>
<authorList>
<person name="Norton J.B."/>
<person name="Cairns N.J."/>
<person name="Chakraverty S."/>
<person name="Wang J."/>
<person name="Levitch D."/>
<person name="Galvin J.E."/>
<person name="Goate A."/>
</authorList>
<dbReference type="PubMed" id="19667325"/>
<dbReference type="DOI" id="10.1212/wnl.0b013e3181b163ba"/>
</citation>
<scope>VARIANT AD3 ARG-217</scope>
<scope>CHARACTERIZATION OF VARIANT AD3 ARG-217</scope>
</reference>
<reference key="120">
<citation type="journal article" date="2010" name="Neurology" volume="74" first="798" last="806">
<title>Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation.</title>
<authorList>
<person name="Bruni A.C."/>
<person name="Bernardi L."/>
<person name="Colao R."/>
<person name="Rubino E."/>
<person name="Smirne N."/>
<person name="Frangipane F."/>
<person name="Terni B."/>
<person name="Curcio S.A."/>
<person name="Mirabelli M."/>
<person name="Clodomiro A."/>
<person name="Di Lorenzo R."/>
<person name="Maletta R."/>
<person name="Anfossi M."/>
<person name="Gallo M."/>
<person name="Geracitano S."/>
<person name="Tomaino C."/>
<person name="Muraca M.G."/>
<person name="Leotta A."/>
<person name="Lio S.G."/>
<person name="Pinessi L."/>
<person name="Rainero I."/>
<person name="Sorbi S."/>
<person name="Nee L."/>
<person name="Milan G."/>
<person name="Pappata S."/>
<person name="Postiglione A."/>
<person name="Abbamondi N."/>
<person name="Forloni G."/>
<person name="St George Hyslop P."/>
<person name="Rogaeva E."/>
<person name="Bugiani O."/>
<person name="Giaccone G."/>
<person name="Foncin J.F."/>
<person name="Spillantini M.G."/>
<person name="Puccio G."/>
</authorList>
<dbReference type="PubMed" id="20164095"/>
<dbReference type="DOI" id="10.1212/wnl.0b013e3181d52785"/>
</citation>
<scope>VARIANT AD3 LEU-146</scope>
</reference>
<reference key="121">
<citation type="journal article" date="2010" name="J. Biol. Chem." volume="285" first="22350" last="22359">
<title>A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.</title>
<authorList>
<person name="Heilig E.A."/>
<person name="Xia W."/>
<person name="Shen J."/>
<person name="Kelleher R.J. III"/>
</authorList>
<dbReference type="PubMed" id="20460383"/>
<dbReference type="DOI" id="10.1074/jbc.m110.116962"/>
</citation>
<scope>VARIANT AD3 PHE-435</scope>
<scope>CHARACTERIZATION OF VARIANTS AD3 PHE-435; GLN-436 AND SER-436</scope>
<scope>MUTAGENESIS OF PRO-433 AND LEU-435</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="122">
<citation type="journal article" date="2011" name="J. Alzheimers Dis." volume="25" first="145" last="150">
<title>Clinical phenotype of G206D mutation in the presenilin 1 gene in pathologically confirmed familial Alzheimer's disease.</title>
<authorList>
<person name="Wu Y.Y."/>
<person name="Cheng I.H."/>
<person name="Lee C.C."/>
<person name="Chiu M.J."/>
<person name="Lee M.J."/>
<person name="Chen T.F."/>
<person name="Hsu J.L."/>
</authorList>
<dbReference type="PubMed" id="21335660"/>
<dbReference type="DOI" id="10.3233/jad-2011-102031"/>
</citation>
<scope>VARIANT AD3 ASP-206</scope>
</reference>
<reference key="123">
<citation type="journal article" date="2011" name="Nature" volume="469" first="539" last="542">
<title>Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.</title>
<authorList>
<person name="Varela I."/>
<person name="Tarpey P."/>
<person name="Raine K."/>
<person name="Huang D."/>
<person name="Ong C.K."/>
<person name="Stephens P."/>
<person name="Davies H."/>
<person name="Jones D."/>
<person name="Lin M.L."/>
<person name="Teague J."/>
<person name="Bignell G."/>
<person name="Butler A."/>
<person name="Cho J."/>
<person name="Dalgliesh G.L."/>
<person name="Galappaththige D."/>
<person name="Greenman C."/>
<person name="Hardy C."/>
<person name="Jia M."/>
<person name="Latimer C."/>
<person name="Lau K.W."/>
<person name="Marshall J."/>
<person name="McLaren S."/>
<person name="Menzies A."/>
<person name="Mudie L."/>
<person name="Stebbings L."/>
<person name="Largaespada D.A."/>
<person name="Wessels L.F.A."/>
<person name="Richard S."/>
<person name="Kahnoski R.J."/>
<person name="Anema J."/>
<person name="Tuveson D.A."/>
<person name="Perez-Mancera P.A."/>
<person name="Mustonen V."/>
<person name="Fischer A."/>
<person name="Adams D.J."/>
<person name="Rust A."/>
<person name="Chan-On W."/>
<person name="Subimerb C."/>
<person name="Dykema K."/>
<person name="Furge K."/>
<person name="Campbell P.J."/>
<person name="Teh B.T."/>
<person name="Stratton M.R."/>
<person name="Futreal P.A."/>
</authorList>
<dbReference type="PubMed" id="21248752"/>
<dbReference type="DOI" id="10.1038/nature09639"/>
</citation>
<scope>VARIANT CYS-315</scope>
</reference>
<reference key="124">
<citation type="journal article" date="2011" name="Neurosci. Lett." volume="496" first="40" last="42">
<title>A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease.</title>
<authorList>
<person name="Antonell A."/>
<person name="Balasa M."/>
<person name="Oliva R."/>
<person name="Llado A."/>
<person name="Bosch B."/>
<person name="Fabregat N."/>
<person name="Fortea J."/>
<person name="Molinuevo J.L."/>
<person name="Sanchez-Valle R."/>
</authorList>
<dbReference type="PubMed" id="21501661"/>
<dbReference type="DOI" id="10.1016/j.neulet.2011.03.084"/>
</citation>
<scope>VARIANT AD3 ARG-235</scope>
</reference>
<reference key="125">
<citation type="journal article" date="2012" name="J. Biol. Chem." volume="287" first="17288" last="17296">
<title>Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase.</title>
<authorList>
<person name="Chau D.M."/>
<person name="Crump C.J."/>
<person name="Villa J.C."/>
<person name="Scheinberg D.A."/>
<person name="Li Y.M."/>
</authorList>
<dbReference type="PubMed" id="22461631"/>
<dbReference type="DOI" id="10.1074/jbc.m111.300483"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 LEU-146; ARG-163 AND ALA-280</scope>
</reference>
<reference key="126">
<citation type="journal article" date="2012" name="Neurobiol. Aging" volume="33" first="1850.E17" last="1850.E27">
<title>Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients.</title>
<authorList>
<person name="Lohmann E."/>
<person name="Guerreiro R.J."/>
<person name="Erginel-Unaltuna N."/>
<person name="Gurunlian N."/>
<person name="Bilgic B."/>
<person name="Gurvit H."/>
<person name="Hanagasi H.A."/>
<person name="Luu N."/>
<person name="Emre M."/>
<person name="Singleton A."/>
</authorList>
<dbReference type="PubMed" id="22503161"/>
<dbReference type="DOI" id="10.1016/j.neurobiolaging.2012.02.020"/>
</citation>
<scope>VARIANTS AD3 ARG-134; ARG-163 AND VAL-262</scope>
<scope>VARIANT TYR-214</scope>
</reference>
<reference key="127">
<citation type="journal article" date="2012" name="Neurosci. Lett." volume="531" first="142" last="144">
<title>Novel presenilin-1 Y159F sequence variant associated with early-onset Alzheimer's disease.</title>
<authorList>
<person name="Kerchner G.A."/>
<person name="Holbrook K."/>
</authorList>
<dbReference type="PubMed" id="23123781"/>
<dbReference type="DOI" id="10.1016/j.neulet.2012.10.037"/>
</citation>
<scope>VARIANT AD3 PHE-159</scope>
</reference>
<reference key="128">
<citation type="journal article" date="2012" name="PLoS ONE" volume="7" first="E35133" last="E35133">
<title>Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified gamma-secretase complexes.</title>
<authorList>
<person name="Cacquevel M."/>
<person name="Aeschbach L."/>
<person name="Houacine J."/>
<person name="Fraering P.C."/>
</authorList>
<dbReference type="PubMed" id="22529981"/>
<dbReference type="DOI" id="10.1371/journal.pone.0035133"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 PRO-166 AND GLN-436</scope>
<scope>MUTAGENESIS OF ASP-257 AND ASP-385</scope>
</reference>
<reference key="129">
<citation type="journal article" date="2013" name="J. Neurosci." volume="33" first="11606" last="11617">
<title>Trans-dominant negative effects of pathogenic PSEN1 mutations on gamma-secretase activity and Abeta production.</title>
<authorList>
<person name="Heilig E.A."/>
<person name="Gutti U."/>
<person name="Tai T."/>
<person name="Shen J."/>
<person name="Kelleher R.J. III"/>
</authorList>
<dbReference type="PubMed" id="23843529"/>
<dbReference type="DOI" id="10.1523/jneurosci.0954-13.2013"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 PRO-166; ILE-278; ALA-384; VAL-392; TYR-410 AND PHE-435</scope>
</reference>
<reference key="130">
<citation type="journal article" date="2014" name="J. Alzheimers Dis." volume="39" first="23" last="27">
<title>A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease.</title>
<authorList>
<person name="Dolzhanskaya N."/>
<person name="Gonzalez M.A."/>
<person name="Sperziani F."/>
<person name="Stefl S."/>
<person name="Messing J."/>
<person name="Wen G.Y."/>
<person name="Alexov E."/>
<person name="Zuchner S."/>
<person name="Velinov M."/>
</authorList>
<dbReference type="PubMed" id="24121961"/>
<dbReference type="DOI" id="10.3233/jad-131340"/>
</citation>
<scope>VARIANT AD3 PHE-381</scope>
</reference>
<reference key="131">
<citation type="journal article" date="2014" name="Neurosci. Lett." volume="563" first="140" last="143">
<title>Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease.</title>
<authorList>
<person name="Cornejo-Olivas M.R."/>
<person name="Yu C.E."/>
<person name="Mazzetti P."/>
<person name="Mata I.F."/>
<person name="Meza M."/>
<person name="Lindo-Samanamud S."/>
<person name="Leverenz J.B."/>
<person name="Bird T.D."/>
</authorList>
<dbReference type="PubMed" id="24495933"/>
<dbReference type="DOI" id="10.1016/j.neulet.2014.01.016"/>
</citation>
<scope>VARIANT AD3 VAL-153</scope>
</reference>
<reference key="132">
<citation type="journal article" date="2014" name="Neurosci. Lett." volume="566" first="115" last="119">
<title>A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease.</title>
<authorList>
<person name="Luedecke D."/>
<person name="Becktepe J.S."/>
<person name="Lehmbeck J.T."/>
<person name="Finckh U."/>
<person name="Yamamoto R."/>
<person name="Jahn H."/>
<person name="Boelmans K."/>
</authorList>
<dbReference type="PubMed" id="24582897"/>
<dbReference type="DOI" id="10.1016/j.neulet.2014.02.034"/>
</citation>
<scope>VARIANT AD3 VAL-275</scope>
</reference>
<reference key="133">
<citation type="journal article" date="2015" name="Neurobiol. Aging" volume="36" first="2904.E09" last="2904.E11">
<title>Novel presenilin 1 mutation (p.I83T) in Tunisian family with early-onset Alzheimer's disease.</title>
<authorList>
<person name="Achouri-Rassas A."/>
<person name="Ben Ali N."/>
<person name="Fray S."/>
<person name="Hadj Fredj S."/>
<person name="Kechaou M."/>
<person name="Zakraoui N.O."/>
<person name="Cherif A."/>
<person name="Chabbi S."/>
<person name="Anane N."/>
<person name="Messaoud T."/>
<person name="Gouider R."/>
<person name="Belal S."/>
</authorList>
<dbReference type="PubMed" id="26145164"/>
<dbReference type="DOI" id="10.1016/j.neurobiolaging.2015.06.007"/>
</citation>
<scope>VARIANT AD3 THR-83</scope>
</reference>
<reference key="134">
<citation type="journal article" date="2016" name="Am. J. Neurodegener. Dis." volume="5" first="94" last="101">
<title>The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida.</title>
<authorList>
<person name="Ravenscroft T.A."/>
<person name="Pottier C."/>
<person name="Murray M.E."/>
<person name="Baker M."/>
<person name="Christopher E."/>
<person name="Levitch D."/>
<person name="Brown P.H."/>
<person name="Barker W."/>
<person name="Duara R."/>
<person name="Greig-Custo M."/>
<person name="Betancourt A."/>
<person name="English M."/>
<person name="Sun X."/>
<person name="Ertekin-Taner N."/>
<person name="Graff-Radford N.R."/>
<person name="Dickson D.W."/>
<person name="Rademakers R."/>
</authorList>
<dbReference type="PubMed" id="27073747"/>
</citation>
<scope>VARIANTS AD3 ALA-206 AND VAL-378</scope>
</reference>
<reference key="135">
<citation type="journal article" date="2016" name="Neurosci. Lett." volume="610" first="150" last="153">
<title>Novel presenilin 1 mutation (Ile408Thr) in an Italian family with late-onset Alzheimer's disease.</title>
<authorList>
<person name="Tedde A."/>
<person name="Bartoli A."/>
<person name="Piaceri I."/>
<person name="Ferrara S."/>
<person name="Bagnoli S."/>
<person name="Serio A."/>
<person name="Sorbi S."/>
<person name="Nacmias B."/>
</authorList>
<dbReference type="PubMed" id="26549787"/>
<dbReference type="DOI" id="10.1016/j.neulet.2015.11.004"/>
</citation>
<scope>VARIANT AD3 THR-408</scope>
</reference>
<reference key="136">
<citation type="journal article" date="2017" name="J. Alzheimers Dis." volume="57" first="613" last="623">
<title>A novel PSEN1 K311R mutation discovered in Chinese families with late-onset Alzheimer's disease affects amyloid-beta production and tau phosphorylation.</title>
<authorList>
<person name="Dong J."/>
<person name="Qin W."/>
<person name="Wei C."/>
<person name="Tang Y."/>
<person name="Wang Q."/>
<person name="Jia J."/>
</authorList>
<dbReference type="PubMed" id="28269784"/>
<dbReference type="DOI" id="10.3233/jad-161188"/>
</citation>
<scope>VARIANT ARG-311</scope>
<scope>CHARACTERIZATION OF VARIANTS ALA-280 AND ARG-311</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="137">
<citation type="journal article" date="2017" name="Proc. Natl. Acad. Sci. U.S.A." volume="114" first="E476" last="E485">
<title>Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase.</title>
<authorList>
<person name="Sun L."/>
<person name="Zhou R."/>
<person name="Yang G."/>
<person name="Shi Y."/>
</authorList>
<dbReference type="PubMed" id="27930341"/>
<dbReference type="DOI" id="10.1073/pnas.1618657114"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS AD3 GLN-35; VAL-79; LEU-82; PRO-85; LEU-89; SER-92; MET-94; PHE-96; LEU-97; HIS-115; ASN-116; ASP-120; LYS-120; ARG-134; ASP-135; VAL-139; THR-143; LEU-146; ILE-147; VAL-153; ASN-154; ARG-163; TYR-163; PRO-166; PRO-169; PHE-170; PRO-171; TRP-173; MET-174; LEU-177; PRO-178; VAL-183; ASP-184; ALA-206; SER-206; ARG-209; VAL-209; LEU-213; ARG-217; ARG-222; PHE-229; THR-231; LEU-233; THR-233; ARG-235; PRO-235; VAL-235; ILE-237; GLU-246; SER-250; VAL-260; PHE-261; PHE-262; ARG-263; LEU-264; SER-266; SER-267; GLY-269; VAL-271; ARG-274; VAL-275; ALA-280; GLY-280; ARG-282; VAL-285; VAL-286; ILE-354; GLN-358; GLU-378; VAL-378; VAL-381; ALA-384; ILE-390; VAL-392; VAL-394; THR-396; SER-405; THR-409; TYR-410; PHE-418; PRO-426; GLU-431; PHE-435; SER-436 AND VAL-439</scope>
<scope>CHARACTERIZATION OF VARIANT CMD1U GLY-333</scope>
<scope>MUTAGENESIS OF THR-99; PHE-105; ARG-108; LEU-113; PRO-117; GLU-123; HIS-131; ALA-136; ILE-143; LEU-150; TRP-165; ILE-168; PHE-176; GLU-184; ILE-202; SER-212; HIS-214; LEU-219; GLN-223; LEU-226; SER-230; ILE-238; LYS-239; THR-245; LEU-248; TYR-256; VAL-272; GLU-273; ARG-278; PRO-284; THR-291; ARG-352; SER-365; ARG-377; PHE-386; VAL-391; VAL-412; LEU-420; LEU-424; ALA-434 AND ILE-437</scope>
</reference>
<reference key="138">
<citation type="journal article" date="2018" name="Int. J. Mol. Sci." volume="19">
<title>PSEN1 p.Thr116Ile variant in two Korean families with young onset Alzheimer's disease.</title>
<authorList>
<person name="Bagyinszky E."/>
<person name="Lee H.M."/>
<person name="Van Giau V."/>
<person name="Koh S.B."/>
<person name="Jeong J.H."/>
<person name="An S.S.A."/>
<person name="Kim S."/>
</authorList>
<dbReference type="PubMed" id="30200536"/>
<dbReference type="DOI" id="10.3390/ijms19092604"/>
</citation>
<scope>VARIANT AD3 ILE-116</scope>
</reference>
<reference key="139">
<citation type="journal article" date="2018" name="J. Neural Transm." volume="125" first="965" last="976">
<title>Neuropathology and biochemistry of early onset familial Alzheimer's disease caused by presenilin-1 missense mutation Thr116Asn.</title>
<authorList>
<person name="Sutovsky S."/>
<person name="Smolek T."/>
<person name="Turcani P."/>
<person name="Petrovic R."/>
<person name="Brandoburova P."/>
<person name="Jadhav S."/>
<person name="Novak P."/>
<person name="Attems J."/>
<person name="Zilka N."/>
</authorList>
<dbReference type="PubMed" id="29404783"/>
<dbReference type="DOI" id="10.1007/s00702-018-1850-z"/>
</citation>
<scope>VARIANT AD3 ASN-116</scope>
</reference>
<reference key="140">
<citation type="journal article" date="2018" name="Neurobiol. Aging" volume="62" first="E15" last="E17">
<title>Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation.</title>
<authorList>
<person name="Wang J.C."/>
<person name="Alinaghi S."/>
<person name="Tafakhori A."/>
<person name="Sikora E."/>
<person name="Azcona L.J."/>
<person name="Karkheiran S."/>
<person name="Goate A."/>
<person name="Paisan-Ruiz C."/>
<person name="Darvish H."/>
</authorList>
<dbReference type="PubMed" id="29175279"/>
<dbReference type="DOI" id="10.1016/j.neurobiolaging.2017.10.011"/>
</citation>
<scope>VARIANTS AD3 PHE-142 AND ASP-206</scope>
</reference>
<reference key="141">
<citation type="journal article" date="2018" name="Neurobiol. Aging" volume="72" first="E13" last="E17">
<title>Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism.</title>
<authorList>
<person name="Giau V.V."/>
<person name="Wang M.J."/>
<person name="Bagyinszky E."/>
<person name="Youn Y.C."/>
<person name="An S.S.A."/>
<person name="Kim S."/>
</authorList>
<dbReference type="PubMed" id="30180983"/>
<dbReference type="DOI" id="10.1016/j.neurobiolaging.2018.08.003"/>
</citation>
<scope>VARIANT AD3 ALA-417</scope>
</reference>
<reference key="142">
<citation type="journal article" date="2018" name="Neurodegener. Dis." volume="18" first="57" last="68">
<title>Phenotypic variability in autosomal dominant familial Alzheimer disease due to the S170F mutation of presenilin-1.</title>
<authorList>
<person name="Tiedt H.O."/>
<person name="Benjamin B."/>
<person name="Niedeggen M."/>
<person name="Lueschow A."/>
</authorList>
<dbReference type="PubMed" id="29466804"/>
<dbReference type="DOI" id="10.1159/000485899"/>
</citation>
<scope>VARIANT AD3 PHE-170</scope>
</reference>
<comment type="function">
<text evidence="13 20 26 28 31 32 43 51 52 55 57 58 64 69 72 79 93 94 97 102 108 109 130">Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein) (PubMed:15274632, PubMed:10545183, PubMed:10593990, PubMed:10206644, PubMed:10899933, PubMed:10811883, PubMed:12679784, PubMed:12740439, PubMed:25043039, PubMed:26280335, PubMed:30598546, PubMed:30630874, PubMed:28269784, PubMed:20460383). Requires the presence of the other members of the gamma-secretase complex for protease activity (PubMed:15274632, PubMed:25043039, PubMed:26280335, PubMed:30598546, PubMed:30630874). Plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels (PubMed:9738936, PubMed:10593990, PubMed:10899933, PubMed:10811883). Stimulates cell-cell adhesion via its interaction with CDH1; this stabilizes the complexes between CDH1 (E-cadherin) and its interaction partners CTNNB1 (beta-catenin), CTNND1 and JUP (gamma-catenin) (PubMed:11953314). Under conditions of apoptosis or calcium influx, cleaves CDH1 (PubMed:11953314). This promotes the disassembly of the complexes between CDH1 and CTNND1, JUP and CTNNB1, increases the pool of cytoplasmic CTNNB1, and thereby negatively regulates Wnt signaling (PubMed:9738936, PubMed:11953314). Required for normal embryonic brain and skeleton development, and for normal angiogenesis (By similarity). Mediates the proteolytic cleavage of EphB2/CTF1 into EphB2/CTF2 (PubMed:17428795, PubMed:28269784). The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is therefore involved in calcium homeostasis (PubMed:25394380, PubMed:16959576). Involved in the regulation of neurite outgrowth (PubMed:15004326, PubMed:20460383). Is a regulator of presynaptic facilitation, spike transmission and synaptic vesicles replenishment in a process that depends on gamma-secretase activity. It acts through the control of SYT7 presynaptic expression (By similarity).</text>
</comment>
<comment type="subunit">
<text evidence="13 17 27 41 43 46 51 52 53 57 63 81 93 94 97 108 109 125 130">Homodimer. The functional gamma-secretase complex is composed of at least four polypeptides: a presenilin homodimer (PSEN1 or PSEN2), nicastrin (NCSTN), APH1 (APH1A or APH1B) and PEN2 (PubMed:15274632, PubMed:12679784, PubMed:12740439, PubMed:25043039, PubMed:26280335, PubMed:25394380, PubMed:30598546, PubMed:30630874). Such minimal complex is sufficient for secretase activity (PubMed:15274632, PubMed:12679784, PubMed:12740439, PubMed:25043039, PubMed:26280335, PubMed:30598546, PubMed:30630874). Other components which are associated with the complex include SLC25A64, SLC5A7, PHB and PSEN1 isoform 3. Predominantly heterodimer of a N-terminal (NTF) and a C-terminal (CTF) endoproteolytical fragment (PubMed:15274632). Associates with proteolytic processed C-terminal fragments C83 and C99 of the amyloid precursor protein (APP) (via transmembrane domain) (PubMed:30630874). Associates with NOTCH1 (via transmembrane domain) (PubMed:10593990, PubMed:30598546). Associates with cadherin/catenin adhesion complexes through direct binding to CDH1 or CDH2 (PubMed:11953314, PubMed:14515347, PubMed:16126725). Interaction with CDH1 stabilizes the complex and stimulates cell-cell aggregation (PubMed:11953314). Interaction with CDH2 is essential for trafficking of CDH2 from the endoplasmic reticulum to the plasma membrane (PubMed:14515347). Interacts with CTNND2, CTNNB1, CTNND1, JUP, HERPUD1, FLNA, FLNB, MTCH1, PKP4 and PARL (PubMed:9738936, PubMed:9437013, PubMed:10551805, PubMed:10037471, PubMed:11953314, PubMed:11799129, PubMed:16126725). Interacts through its N-terminus with isoform 3 of GFAP (PubMed:12058025). Interacts with DOCK3 (By similarity). Interacts with isoform 1 and isoform 3 of UBQLN1 (PubMed:21143716).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-368690">
<id>Q02410</id>
<label>APBA1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-77613">
<id>P05067</id>
<label>APP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-302641">
<id>P05067-4</id>
<label>APP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-2433139">
<id>P56817</id>
<label>BACE1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-295634">
<id>Q16543</id>
<label>CDC37</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-712452">
<id>Q9BQ95</id>
<label>ECSIT</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-348613">
<id>Q14254</id>
<label>FLOT2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-1267511">
<id>P17677</id>
<label>GAP43</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-1751885">
<id>Q9UL51</id>
<label>HCN2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-998440">
<id>Q92542</id>
<label>NCSTN</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-998468">
<id>Q9NZ42</id>
<label>PSENEN</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-18082698">
<id>Q96QE2</id>
<label>SLC2A13</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-725116">
<id>P11169</id>
<label>SLC2A3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-357285">
<id>P50502</id>
<label>ST13</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-960169">
<id>P61764</id>
<label>STXBP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-1045825">
<id>P55061</id>
<label>TMBIM6</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>12</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-998422">
<id>P49755</id>
<label>TMED10</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-14036387">
<id>Q9NZC2</id>
<label>TREM2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-297277">
<id>P49768</id>
</interactant>
<interactant intactId="EBI-81669">
<id>P98084</id>
<label>Apba2</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-11047108">
<id>P49768-2</id>
</interactant>
<interactant intactId="EBI-998468">
<id>Q9NZ42</id>
<label>PSENEN</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-11047108">
<id>P49768-2</id>
</interactant>
<interactant intactId="EBI-18159983">
<id>Q3KNW5</id>
<label>SLC10A6</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2606326">
<id>PRO_0000025591</id>
</interactant>
<interactant intactId="EBI-5275794">
<id>Q63053</id>
<label>Arc</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2606356">
<id>PRO_0000025592</id>
</interactant>
<interactant intactId="EBI-750709">
<id>P35613</id>
<label>BSG</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2606356">
<id>PRO_0000025592</id>
</interactant>
<interactant intactId="EBI-998440">
<id>Q92542</id>
<label>NCSTN</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="94">Endoplasmic reticulum</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="28 113 130 143 146">Endoplasmic reticulum membrane</location>
<topology evidence="93 95 97 99 108 109">Multi-pass membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="28 113 143 146">Golgi apparatus membrane</location>
<topology evidence="93 95 97 99 108 109">Multi-pass membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="44">Cytoplasmic granule</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="28 43 44 81">Cell membrane</location>
<topology evidence="95 99 108 109">Multi-pass membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="55">Cell projection</location>
<location evidence="55">Growth cone</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="94">Early endosome</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="149">Early endosome membrane</location>
<topology evidence="95 99 108 109">Multi-pass membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="55">Cell projection</location>
<location evidence="55">Neuron projection</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="15">Cell projection</location>
<location evidence="15">Axon</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="15">Cell junction</location>
<location evidence="15">Synapse</location>
</subcellularLocation>
<text evidence="28 44 81 130">Translocates with bound NOTCH1 from the endoplasmic reticulum and/or Golgi to the cell surface (PubMed:10593990). Colocalizes with CDH1/2 at sites of cell-cell contact. Colocalizes with CTNNB1 in the endoplasmic reticulum and the proximity of the plasma membrane (PubMed:9738936). Also present in azurophil granules of neutrophils (PubMed:11987239). Colocalizes with UBQLN1 in the cell membrane and in cytoplasmic juxtanuclear structures called aggresomes (PubMed:21143716).</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P49768-1</id>
<name>1</name>
<name>I-467</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P49768-2</id>
<name>2</name>
<name>I-463</name>
<sequence type="described" ref="VSP_005191"/>
</isoform>
<isoform>
<id>P49768-3</id>
<name>3</name>
<name>I-374</name>
<sequence type="described" ref="VSP_005191 VSP_005192"/>
</isoform>
<isoform>
<id>P49768-4</id>
<name>4</name>
<name>Minilin</name>
<sequence type="described" ref="VSP_007986 VSP_007987"/>
</isoform>
<isoform>
<id>P49768-5</id>
<name>5</name>
<sequence type="described" ref="VSP_005192"/>
</isoform>
<isoform>
<id>P49768-6</id>
<name>6</name>
<sequence type="described" ref="VSP_012288"/>
</isoform>
<isoform>
<id>P49768-7</id>
<name>7</name>
<sequence type="described" ref="VSP_041440"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="44 111 113 116">Detected in azurophile granules in neutrophils and in platelet cytoplasmic granules (at protein level) (PubMed:11987239). Expressed in a wide range of tissues including various regions of the brain, liver, spleen and lymph nodes (PubMed:7596406, PubMed:8641442, PubMed:8574969).</text>
</comment>
<comment type="domain">
<text evidence="64">The PAL motif is required for normal active site conformation.</text>
</comment>
<comment type="domain">
<text evidence="108 109">Substrates, such as NOTCH1 and APP peptides, are bound between PSEN1 transmembrane domains and via the first lumenal loop and the cytoplasmic loop between the sixth and seventh transmembrane domains. Substrate binding causes a conformation change and formation of an intermolecular antiparallel beta-sheet between PSEN1 and its substrates.</text>
</comment>
<comment type="PTM">
<text evidence="26 57 121 126">Heterogeneous proteolytic processing generates N-terminal (NTF) and C-terminal (CTF) fragments of approximately 35 and 20 kDa, respectively. During apoptosis, the C-terminal fragment (CTF) is further cleaved by caspase-3 to produce the fragment, PS1-CTF12.</text>
</comment>
<comment type="PTM">
<text evidence="54 119">After endoproteolysis, the C-terminal fragment (CTF) is phosphorylated on serine residues by PKA and/or PKC. Phosphorylation on Ser-346 inhibits endoproteolysis.</text>
</comment>
<comment type="disease" evidence="16 18 19 21 22 23 24 25 29 30 33 35 36 37 38 39 40 42 45 46 47 48 49 50 55 56 59 60 61 62 64 65 66 67 68 69 71 72 73 74 76 77 78 79 83 84 85 86 87 88 89 90 91 92 94 96 97 98 100 101 103 104 105 106 107 110 111 112 114 115 117 118 120 122 123 124 127 128 129 131 132 136">
<disease id="DI-00086">
<name>Alzheimer disease 3</name>
<acronym>AD3</acronym>
<description>A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.</description>
<dbReference type="MIM" id="607822"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="34">
<disease id="DI-01632">
<name>Frontotemporal dementia</name>
<acronym>FTD</acronym>
<description>A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.</description>
<dbReference type="MIM" id="600274"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="70 101">
<disease id="DI-02967">
<name>Cardiomyopathy, dilated 1U</name>
<acronym>CMD1U</acronym>
<description>A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.</description>
<dbReference type="MIM" id="613694"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="80">
<disease id="DI-02997">
<name>Acne inversa, familial, 3</name>
<acronym>ACNINV3</acronym>
<description>A chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty.</description>
<dbReference type="MIM" id="613737"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="56">
<disease id="DI-02937">
<name>Pick disease of the brain</name>
<acronym>PIDB</acronym>
<description>A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.</description>
<dbReference type="MIM" id="172700"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform 3</molecule>
<text evidence="142">May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.</text>
</comment>
<comment type="similarity">
<text evidence="142">Belongs to the peptidase A22A family.</text>
</comment>
<comment type="online information" name="Alzheimer Research Forum">
<link uri="https://www.alzforum.org/mutations/search?genes%255B%255D=348"/>
<text>Presenilins mutations</text>
</comment>
<dbReference type="EC" id="3.4.23.-" evidence="20 31 32 51 57 97"/>
<dbReference type="EMBL" id="L42110">
<property type="protein sequence ID" value="AAB46416.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L76517">
<property type="protein sequence ID" value="AAB46370.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L76528">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76519">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76520">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76521">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76522">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76523">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76524">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76525">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76526">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L76527">
<property type="protein sequence ID" value="AAB46371.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="U40379">
<property type="protein sequence ID" value="AAB05894.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U40380">
<property type="protein sequence ID" value="AAB05895.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AJ008005">
<property type="protein sequence ID" value="CAA07825.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF109907">
<property type="protein sequence ID" value="AAC97960.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF416717">
<property type="protein sequence ID" value="AAL16811.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK312531">
<property type="protein sequence ID" value="BAG35430.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC004858">
<property type="protein sequence ID" value="AAF19253.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC004858">
<property type="protein sequence ID" value="AAF19254.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471061">
<property type="protein sequence ID" value="EAW81092.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC011729">
<property type="protein sequence ID" value="AAH11729.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="D84149">
<property type="protein sequence ID" value="BAA20883.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS9812.1">
<molecule id="P49768-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS9813.1">
<molecule id="P49768-2"/>
</dbReference>
<dbReference type="PIR" id="S58396">
<property type="entry name" value="S58396"/>
</dbReference>
<dbReference type="PIR" id="S63683">
<property type="entry name" value="S63683"/>
</dbReference>
<dbReference type="PIR" id="S63684">
<property type="entry name" value="S63684"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000012.1">
<molecule id="P49768-1"/>
<property type="nucleotide sequence ID" value="NM_000021.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_015557.2">
<molecule id="P49768-2"/>
<property type="nucleotide sequence ID" value="NM_007318.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_005267921.1">
<molecule id="P49768-1"/>
<property type="nucleotide sequence ID" value="XM_005267864.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_005267923.1">
<molecule id="P49768-2"/>
<property type="nucleotide sequence ID" value="XM_005267866.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011535273.1">
<property type="nucleotide sequence ID" value="XM_011536971.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011535274.1">
<molecule id="P49768-1"/>
<property type="nucleotide sequence ID" value="XM_011536972.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011535275.1">
<molecule id="P49768-2"/>
<property type="nucleotide sequence ID" value="XM_011536973.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011535276.1">
<molecule id="P49768-2"/>
<property type="nucleotide sequence ID" value="XM_011536974.1"/>
</dbReference>
<dbReference type="PDB" id="2KR6">
<property type="method" value="NMR"/>
<property type="chains" value="A=292-467"/>
</dbReference>
<dbReference type="PDB" id="4UIS">
<property type="method" value="EM"/>
<property type="resolution" value="4.40"/>
<property type="chains" value="B=81-463"/>
</dbReference>
<dbReference type="PDB" id="5A63">
<property type="method" value="EM"/>
<property type="resolution" value="3.40"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="5FN2">
<property type="method" value="EM"/>
<property type="resolution" value="4.20"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="5FN3">
<property type="method" value="EM"/>
<property type="resolution" value="4.10"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="5FN4">
<property type="method" value="EM"/>
<property type="resolution" value="4.00"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="5FN5">
<property type="method" value="EM"/>
<property type="resolution" value="4.30"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="6IDF">
<property type="method" value="EM"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDB" id="6IYC">
<property type="method" value="EM"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="B=1-467"/>
</dbReference>
<dbReference type="PDBsum" id="2KR6"/>
<dbReference type="PDBsum" id="4UIS"/>
<dbReference type="PDBsum" id="5A63"/>
<dbReference type="PDBsum" id="5FN2"/>
<dbReference type="PDBsum" id="5FN3"/>
<dbReference type="PDBsum" id="5FN4"/>
<dbReference type="PDBsum" id="5FN5"/>
<dbReference type="PDBsum" id="6IDF"/>
<dbReference type="PDBsum" id="6IYC"/>
<dbReference type="SMR" id="P49768"/>
<dbReference type="BioGRID" id="111642">
<property type="interactions" value="171"/>
</dbReference>
<dbReference type="ComplexPortal" id="CPX-2176">
<property type="entry name" value="Gamma-secretase complex, APH1A-PSEN1 variant"/>
</dbReference>
<dbReference type="ComplexPortal" id="CPX-4233">
<property type="entry name" value="Gamma-secretase complex, APH1B-PSEN1 variant"/>
</dbReference>
<dbReference type="CORUM" id="P49768"/>
<dbReference type="DIP" id="DIP-1134N"/>
<dbReference type="ELM" id="P49768"/>
<dbReference type="IntAct" id="P49768">
<property type="interactions" value="224"/>
</dbReference>
<dbReference type="MINT" id="P49768"/>
<dbReference type="STRING" id="9606.ENSP00000326366"/>
<dbReference type="BindingDB" id="P49768"/>
<dbReference type="ChEMBL" id="CHEMBL2473"/>
<dbReference type="GuidetoPHARMACOLOGY" id="2402"/>
<dbReference type="MEROPS" id="A22.001"/>
<dbReference type="TCDB" id="1.A.54.1.1">
<property type="family name" value="the presenilin er ca(2+) leak channel (presenilin) family"/>
</dbReference>
<dbReference type="iPTMnet" id="P49768"/>
<dbReference type="PhosphoSitePlus" id="P49768"/>
<dbReference type="SwissPalm" id="P49768"/>
<dbReference type="BioMuta" id="PSEN1"/>
<dbReference type="DMDM" id="1709856"/>
<dbReference type="EPD" id="P49768"/>
<dbReference type="jPOST" id="P49768"/>
<dbReference type="MassIVE" id="P49768"/>
<dbReference type="MaxQB" id="P49768"/>
<dbReference type="PaxDb" id="P49768"/>
<dbReference type="PeptideAtlas" id="P49768"/>
<dbReference type="PRIDE" id="P49768"/>
<dbReference type="ProteomicsDB" id="56106">
<molecule id="P49768-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56107">
<molecule id="P49768-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56108">
<molecule id="P49768-3"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56109">
<molecule id="P49768-4"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56110">
<molecule id="P49768-5"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56111">
<molecule id="P49768-6"/>
</dbReference>
<dbReference type="ProteomicsDB" id="56112">
<molecule id="P49768-7"/>
</dbReference>
<dbReference type="Antibodypedia" id="3480">
<property type="antibodies" value="947 antibodies"/>
</dbReference>
<dbReference type="DNASU" id="5663"/>
<dbReference type="Ensembl" id="ENST00000324501">
<molecule id="P49768-1"/>
<property type="protein sequence ID" value="ENSP00000326366"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000357710">
<molecule id="P49768-2"/>
<property type="protein sequence ID" value="ENSP00000350342"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000394157">
<molecule id="P49768-4"/>
<property type="protein sequence ID" value="ENSP00000377712"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000394164">
<molecule id="P49768-2"/>
<property type="protein sequence ID" value="ENSP00000377719"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000553855">
<molecule id="P49768-5"/>
<property type="protein sequence ID" value="ENSP00000452242"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000555386">
<molecule id="P49768-3"/>
<property type="protein sequence ID" value="ENSP00000450845"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000557511">
<molecule id="P49768-6"/>
<property type="protein sequence ID" value="ENSP00000451429"/>
<property type="gene ID" value="ENSG00000080815"/>
</dbReference>
<dbReference type="GeneID" id="5663"/>
<dbReference type="KEGG" id="hsa:5663"/>
<dbReference type="UCSC" id="uc001xnq.5">
<molecule id="P49768-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="5663"/>
<dbReference type="DisGeNET" id="5663"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000080815.18"/>
<dbReference type="GeneCards" id="PSEN1"/>
<dbReference type="GeneReviews" id="PSEN1"/>
<dbReference type="HGNC" id="HGNC:9508">
<property type="gene designation" value="PSEN1"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000080815">
<property type="expression patterns" value="Low tissue specificity"/>
</dbReference>
<dbReference type="MalaCards" id="PSEN1"/>
<dbReference type="MIM" id="104311">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="172700">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="600274">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="607822">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="613694">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="613737">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P49768"/>
<dbReference type="NIAGADS" id="ENSG00000080815"/>
<dbReference type="OpenTargets" id="ENSG00000080815"/>
<dbReference type="Orphanet" id="275864">
<property type="disease" value="Behavioral variant of frontotemporal dementia"/>
</dbReference>
<dbReference type="Orphanet" id="1020">
<property type="disease" value="Early-onset autosomal dominant Alzheimer disease"/>
</dbReference>
<dbReference type="Orphanet" id="154">
<property type="disease" value="Familial isolated dilated cardiomyopathy"/>
</dbReference>
<dbReference type="Orphanet" id="387">
<property type="disease" value="NON RARE IN EUROPE: Hidradenitis suppurativa"/>
</dbReference>
<dbReference type="Orphanet" id="100070">
<property type="disease" value="Progressive non-fluent aphasia"/>
</dbReference>
<dbReference type="Orphanet" id="100069">
<property type="disease" value="Semantic dementia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA33855"/>
<dbReference type="eggNOG" id="KOG2736">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00940000158751"/>
<dbReference type="HOGENOM" id="CLU_022975_3_0_1"/>
<dbReference type="InParanoid" id="P49768"/>
<dbReference type="KO" id="K04505"/>
<dbReference type="OMA" id="MYYQDID"/>
<dbReference type="PhylomeDB" id="P49768"/>
<dbReference type="TreeFam" id="TF315040"/>
<dbReference type="PathwayCommons" id="P49768"/>
<dbReference type="Reactome" id="R-HSA-1251985">
<property type="pathway name" value="Nuclear signaling by ERBB4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1474228">
<property type="pathway name" value="Degradation of the extracellular matrix"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-193692">
<property type="pathway name" value="Regulated proteolysis of p75NTR"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-205043">
<property type="pathway name" value="NRIF signals cell death from the nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2122948">
<property type="pathway name" value="Activated NOTCH1 Transmits Signal to the Nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2644606">
<property type="pathway name" value="Constitutive Signaling by NOTCH1 PEST Domain Mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2894862">
<property type="pathway name" value="Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2979096">
<property type="pathway name" value="NOTCH2 Activation and Transmission of Signal to the Nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3928665">
<property type="pathway name" value="EPH-ephrin mediated repulsion of cells"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6798695">
<property type="pathway name" value="Neutrophil degranulation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9013507">
<property type="pathway name" value="NOTCH3 Activation and Transmission of Signal to the Nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9013700">
<property type="pathway name" value="NOTCH4 Activation and Transmission of Signal to the Nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9017802">
<property type="pathway name" value="Noncanonical activation of NOTCH3"/>
</dbReference>
<dbReference type="SignaLink" id="P49768"/>
<dbReference type="SIGNOR" id="P49768"/>
<dbReference type="BioGRID-ORCS" id="5663">
<property type="hits" value="10 hits in 883 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="PSEN1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P49768"/>
<dbReference type="GeneWiki" id="PSEN1"/>
<dbReference type="GenomeRNAi" id="5663"/>
<dbReference type="Pharos" id="P49768">
<property type="development level" value="Tchem"/>
</dbReference>
<dbReference type="PRO" id="PR:P49768"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 14"/>
</dbReference>
<dbReference type="RNAct" id="P49768">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000080815">
<property type="expression patterns" value="Expressed in corpus callosum and 239 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P49768">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P49768">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0016235">
<property type="term" value="C:aggresome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016324">
<property type="term" value="C:apical plasma membrane"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0030424">
<property type="term" value="C:axon"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0035577">
<property type="term" value="C:azurophil granule membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005938">
<property type="term" value="C:cell cortex"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0030054">
<property type="term" value="C:cell junction"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0009986">
<property type="term" value="C:cell surface"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005813">
<property type="term" value="C:centrosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035253">
<property type="term" value="C:ciliary rootlet"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0043198">
<property type="term" value="C:dendritic shaft"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0031901">
<property type="term" value="C:early endosome membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005789">
<property type="term" value="C:endoplasmic reticulum membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0070765">
<property type="term" value="C:gamma-secretase complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000139">
<property type="term" value="C:Golgi membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0030426">
<property type="term" value="C:growth cone"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016021">
<property type="term" value="C:integral component of membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0099056">
<property type="term" value="C:integral component of presynaptic membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000776">
<property type="term" value="C:kinetochore"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005765">
<property type="term" value="C:lysosomal membrane"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0016020">
<property type="term" value="C:membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0045121">
<property type="term" value="C:membrane raft"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005743">
<property type="term" value="C:mitochondrial inner membrane"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005739">
<property type="term" value="C:mitochondrion"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031594">
<property type="term" value="C:neuromuscular junction"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0043005">
<property type="term" value="C:neuron projection"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043025">
<property type="term" value="C:neuronal cell body"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0031965">
<property type="term" value="C:nuclear membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005640">
<property type="term" value="C:nuclear outer membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0048471">
<property type="term" value="C:perinuclear region of cytoplasm"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032991">
<property type="term" value="C:protein-containing complex"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0005791">
<property type="term" value="C:rough endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042383">
<property type="term" value="C:sarcolemma"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005790">
<property type="term" value="C:smooth endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008021">
<property type="term" value="C:synaptic vesicle"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030018">
<property type="term" value="C:Z disc"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0042500">
<property type="term" value="F:aspartic endopeptidase activity, intramembrane cleaving"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004190">
<property type="term" value="F:aspartic-type endopeptidase activity"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051117">
<property type="term" value="F:ATPase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008013">
<property type="term" value="F:beta-catenin binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045296">
<property type="term" value="F:cadherin binding"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005262">
<property type="term" value="F:calcium channel activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004175">
<property type="term" value="F:endopeptidase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0070851">
<property type="term" value="F:growth factor receptor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030165">
<property type="term" value="F:PDZ domain binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000186">
<property type="term" value="P:activation of MAPKK activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042987">
<property type="term" value="P:amyloid precursor protein catabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0042982">
<property type="term" value="P:amyloid precursor protein metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034205">
<property type="term" value="P:amyloid-beta formation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050435">
<property type="term" value="P:amyloid-beta metabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0048143">
<property type="term" value="P:astrocyte activation"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0002265">
<property type="term" value="P:astrocyte activation involved in immune response"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0000045">
<property type="term" value="P:autophagosome assembly"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001568">
<property type="term" value="P:blood vessel development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048854">
<property type="term" value="P:brain morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0021870">
<property type="term" value="P:Cajal-Retzius cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006816">
<property type="term" value="P:calcium ion transport"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0001708">
<property type="term" value="P:cell fate specification"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0098609">
<property type="term" value="P:cell-cell adhesion"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:1904646">
<property type="term" value="P:cellular response to amyloid-beta"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006974">
<property type="term" value="P:cellular response to DNA damage stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0021549">
<property type="term" value="P:cerebellum development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0021795">
<property type="term" value="P:cerebral cortex cell migration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0015871">
<property type="term" value="P:choline transport"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0021904">
<property type="term" value="P:dorsal/ventral neural tube patterning"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030326">
<property type="term" value="P:embryonic limb morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032469">
<property type="term" value="P:endoplasmic reticulum calcium ion homeostasis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0048013">
<property type="term" value="P:ephrin receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0050673">
<property type="term" value="P:epithelial cell proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001947">
<property type="term" value="P:heart looping"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002244">
<property type="term" value="P:hematopoietic progenitor cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035556">
<property type="term" value="P:intracellular signal transduction"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0007611">
<property type="term" value="P:learning or memory"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006509">
<property type="term" value="P:membrane protein ectodomain proteolysis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0031293">
<property type="term" value="P:membrane protein intracellular domain proteolysis"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007613">
<property type="term" value="P:memory"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006839">
<property type="term" value="P:mitochondrial transport"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0090647">
<property type="term" value="P:modulation of age-related behavioral decline"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043011">
<property type="term" value="P:myeloid dendritic cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001234">
<property type="term" value="P:negative regulation of apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050771">
<property type="term" value="P:negative regulation of axonogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1904797">
<property type="term" value="P:negative regulation of core promoter binding"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0007175">
<property type="term" value="P:negative regulation of epidermal growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010629">
<property type="term" value="P:negative regulation of gene expression"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043524">
<property type="term" value="P:negative regulation of neuron apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000122">
<property type="term" value="P:negative regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:2000059">
<property type="term" value="P:negative regulation of ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051444">
<property type="term" value="P:negative regulation of ubiquitin-protein transferase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0003407">
<property type="term" value="P:neural retina development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051402">
<property type="term" value="P:neuron apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048666">
<property type="term" value="P:neuron development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001764">
<property type="term" value="P:neuron migration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1990535">
<property type="term" value="P:neuron projection maintenance"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043312">
<property type="term" value="P:neutrophil degranulation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007220">
<property type="term" value="P:Notch receptor processing"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0035333">
<property type="term" value="P:Notch receptor processing, ligand-dependent"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:1905908">
<property type="term" value="P:positive regulation of amyloid fibril formation"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043065">
<property type="term" value="P:positive regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043085">
<property type="term" value="P:positive regulation of catalytic activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0050820">
<property type="term" value="P:positive regulation of coagulation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0060999">
<property type="term" value="P:positive regulation of dendritic spine development"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CACAO"/>
</dbReference>
<dbReference type="GO" id="GO:0010628">
<property type="term" value="P:positive regulation of gene expression"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045821">
<property type="term" value="P:positive regulation of glycolytic process"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0002038">
<property type="term" value="P:positive regulation of L-glutamate import across plasma membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042327">
<property type="term" value="P:positive regulation of phosphorylation"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032436">
<property type="term" value="P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032092">
<property type="term" value="P:positive regulation of protein binding"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042307">
<property type="term" value="P:positive regulation of protein import into nucleus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001921">
<property type="term" value="P:positive regulation of receptor recycling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CACAO"/>
</dbReference>
<dbReference type="GO" id="GO:0042535">
<property type="term" value="P:positive regulation of tumor necrosis factor biosynthetic process"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0009791">
<property type="term" value="P:post-embryonic development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006486">
<property type="term" value="P:protein glycosylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016485">
<property type="term" value="P:protein processing"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0015031">
<property type="term" value="P:protein transport"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0060828">
<property type="term" value="P:regulation of canonical Wnt signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010468">
<property type="term" value="P:regulation of gene expression"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010975">
<property type="term" value="P:regulation of neuron projection development"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042325">
<property type="term" value="P:regulation of phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060075">
<property type="term" value="P:regulation of resting membrane potential"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048167">
<property type="term" value="P:regulation of synaptic plasticity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051966">
<property type="term" value="P:regulation of synaptic transmission, glutamatergic"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006979">
<property type="term" value="P:response to oxidative stress"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048705">
<property type="term" value="P:skeletal system morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043589">
<property type="term" value="P:skin morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051563">
<property type="term" value="P:smooth endoplasmic reticulum calcium ion homeostasis"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0001756">
<property type="term" value="P:somitogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050808">
<property type="term" value="P:synapse organization"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016080">
<property type="term" value="P:synaptic vesicle targeting"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002286">
<property type="term" value="P:T cell activation involved in immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050852">
<property type="term" value="P:T cell receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048538">
<property type="term" value="P:thymus development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="DisProt" id="DP01292"/>
<dbReference type="Gene3D" id="1.10.472.100">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR002031">
<property type="entry name" value="Pept_A22A_PS1"/>
</dbReference>
<dbReference type="InterPro" id="IPR001108">
<property type="entry name" value="Peptidase_A22A"/>
</dbReference>
<dbReference type="InterPro" id="IPR006639">
<property type="entry name" value="Preselin/SPP"/>
</dbReference>
<dbReference type="InterPro" id="IPR042524">
<property type="entry name" value="Presenilin_C"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR10202">
<property type="entry name" value="PTHR10202"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF01080">
<property type="entry name" value="Presenilin"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR01072">
<property type="entry name" value="PRESENILIN"/>
</dbReference>
<dbReference type="PRINTS" id="PR01073">
<property type="entry name" value="PRESENILIN1"/>
</dbReference>
<dbReference type="SMART" id="SM00730">
<property type="entry name" value="PSN"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0026">Alzheimer disease</keyword>
<keyword id="KW-1008">Amyloidosis</keyword>
<keyword id="KW-0053">Apoptosis</keyword>
<keyword id="KW-0122">Cardiomyopathy</keyword>
<keyword id="KW-0130">Cell adhesion</keyword>
<keyword id="KW-0965">Cell junction</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0966">Cell projection</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0967">Endosome</keyword>
<keyword id="KW-0333">Golgi apparatus</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0523">Neurodegeneration</keyword>
<keyword id="KW-0914">Notch signaling pathway</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0645">Protease</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0770">Synapse</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<feature type="chain" description="Presenilin-1 NTF subunit" id="PRO_0000025591">
<location>
<begin position="1"/>
<end position="298"/>
</location>
</feature>
<feature type="chain" description="Presenilin-1 CTF subunit" id="PRO_0000025592">
<location>
<begin position="299"/>
<end position="467"/>
</location>
</feature>
<feature type="chain" description="Presenilin-1 CTF12" id="PRO_0000236055">
<location>
<begin position="346"/>
<end position="467"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="97">
<location>
<begin position="1"/>
<end position="82"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="83"/>
<end position="103"/>
</location>
</feature>
<feature type="topological domain" description="Lumenal" evidence="97">
<location>
<begin position="104"/>
<end position="132"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="133"/>
<end position="153"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="97">
<location>
<begin position="154"/>
<end position="166"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="167"/>
<end position="189"/>
</location>
</feature>
<feature type="topological domain" description="Lumenal" evidence="97">
<location>
<begin position="190"/>
<end position="194"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="195"/>
<end position="216"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="97">
<location>
<begin position="217"/>
<end position="220"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="221"/>
<end position="241"/>
</location>
</feature>
<feature type="topological domain" description="Lumenal" evidence="97">
<location>
<begin position="242"/>
<end position="248"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="249"/>
<end position="272"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="97">
<location>
<begin position="273"/>
<end position="380"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="381"/>
<end position="401"/>
</location>
</feature>
<feature type="topological domain" description="Lumenal" evidence="97">
<location>
<begin position="402"/>
<end position="407"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="408"/>
<end position="428"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="97">
<location>
<begin position="429"/>
<end position="432"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="97">
<location>
<begin position="433"/>
<end position="453"/>
</location>
</feature>
<feature type="topological domain" description="Lumenal" evidence="97">
<location>
<begin position="454"/>
<end position="467"/>
</location>
</feature>
<feature type="region of interest" description="Important for cleavage of target proteins" evidence="108">
<location>
<begin position="288"/>
<end position="290"/>
</location>
</feature>
<feature type="region of interest" description="Required for interaction with CTNNB1" evidence="130">
<location>
<begin position="322"/>
<end position="450"/>
</location>
</feature>
<feature type="region of interest" description="Required for interaction with CTNND2" evidence="17">
<location>
<begin position="372"/>
<end position="399"/>
</location>
</feature>
<feature type="region of interest" description="Important for cleavage of target proteins" evidence="108">
<location>
<begin position="377"/>
<end position="381"/>
</location>
</feature>
<feature type="region of interest" description="Important for cleavage of target proteins" evidence="108">
<location>
<begin position="432"/>
<end position="434"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with MTCH1" evidence="27">
<location>
<begin position="464"/>
<end position="467"/>
</location>
</feature>
<feature type="short sequence motif" description="PAL" evidence="148">
<location>
<begin position="433"/>
<end position="435"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Val">
<location>
<begin position="94"/>
<end position="97"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Leu">
<location>
<begin position="171"/>
<end position="174"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Leu">
<location>
<begin position="418"/>
<end position="425"/>
</location>
</feature>
<feature type="active site" evidence="144 145 147">
<location>
<position position="257"/>
</location>
</feature>
<feature type="active site" evidence="144 145 147 150 151">
<location>
<position position="385"/>
</location>
</feature>
<feature type="site" description="Cleavage; alternate" evidence="121">
<location>
<begin position="291"/>
<end position="292"/>
</location>
</feature>
<feature type="site" description="Cleavage; alternate" evidence="121">
<location>
<begin position="292"/>
<end position="293"/>
</location>
</feature>
<feature type="site" description="Cleavage" evidence="121">
<location>
<begin position="298"/>
<end position="299"/>
</location>
</feature>
<feature type="site" description="Cleavage; by caspase" evidence="126">
<location>
<begin position="345"/>
<end position="346"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10 11 12">
<location>
<position position="43"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="14">
<location>
<position position="51"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKA" evidence="54">
<location>
<position position="310"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKC" evidence="54">
<location>
<position position="346"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11 12">
<location>
<position position="367"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2 and isoform 3." id="VSP_005191" evidence="137 138 139">
<location>
<begin position="26"/>
<end position="29"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_007986" evidence="140">
<original>IHAWLIISSLLLLFFFSFIYLGE</original>
<variation>SMRHRSLLSTLFFLWLGILVTVT</variation>
<location>
<begin position="162"/>
<end position="184"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_007987" evidence="140">
<location>
<begin position="185"/>
<end position="467"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 7." id="VSP_041440" evidence="142">
<location>
<begin position="257"/>
<end position="289"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3 and isoform 5." id="VSP_005192" evidence="139 141">
<original>STERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI</original>
<variation>RACLPPAAINLLSIAPMAPRLFMPKGACRPTAQKGSHKTLLQRMMMAGSVRNGKPRGTVI</variation>
<location>
<begin position="319"/>
<end position="467"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 6." id="VSP_012288" evidence="142">
<location>
<begin position="319"/>
<end position="376"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; decreased protease activity with APP; dbSNP:rs63750592." id="VAR_075260" evidence="35 101">
<original>R</original>
<variation>Q</variation>
<location>
<position position="35"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; also found in late-onset Alzheimer disease; impaired protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; no effect on interaction with GFAP; dbSNP:rs63749824." id="VAR_006413" evidence="29 35 46 67 71 101 124">
<original>A</original>
<variation>V</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; no effect on interaction with GFAP; dbSNP:rs63749967." id="VAR_006414" evidence="23 46 101 115">
<original>V</original>
<variation>L</variation>
<location>
<position position="82"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3." id="VAR_075261" evidence="96">
<original>I</original>
<variation>T</variation>
<location>
<position position="83"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; the patient also manifest spastic paraparesis and apraxia; loss of protease activity with APP in vitro; altered amyloid-beta production in cells transfected with the mutant and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750599." id="VAR_081228" evidence="60 101">
<original>L</original>
<variation>P</variation>
<location>
<position position="85"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750815." id="VAR_081229" evidence="40">
<original>V</original>
<variation>L</variation>
<location>
<position position="89"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; loss of protease activity with APP; dbSNP:rs63751141." id="VAR_016214" evidence="33 101">
<original>C</original>
<variation>S</variation>
<location>
<position position="92"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; reduced protease activity with APP; no relevant change in amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750831." id="VAR_081230" evidence="37">
<original>V</original>
<variation>M</variation>
<location>
<position position="94"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; loss of protease activity with APP; dbSNP:rs63750601." id="VAR_006415" evidence="101 117">
<original>V</original>
<variation>F</variation>
<location>
<position position="96"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; slightly reduced protease activity with APP; dbSNP:rs63750852." id="VAR_081231" evidence="62 101">
<original>V</original>
<variation>L</variation>
<location>
<position position="97"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750321." id="VAR_009208" evidence="29">
<original>F</original>
<variation>L</variation>
<location>
<position position="105"/>
</location>
</feature>
<feature type="sequence variant" description="In frontotemporal dementia; dbSNP:rs63751399." id="VAR_016215" evidence="34">
<original>L</original>
<variation>P</variation>
<location>
<position position="113"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750450." id="VAR_006416" evidence="35 50 124">
<original>Y</original>
<variation>C</variation>
<location>
<position position="115"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired protease activity with APP and increased amyloid-beta 42/amyloid-beta 40 ratio." id="VAR_006417" evidence="23 101 115">
<original>Y</original>
<variation>H</variation>
<location>
<position position="115"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750730." id="VAR_081232" evidence="107">
<original>T</original>
<variation>I</variation>
<location>
<position position="116"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unusual amyloid cotton wool plaques detected in one patient's brain; severe decrease of protease activity with APP; results in increased amyloid-beta 42/amyloid-beta 40 ratio." id="VAR_010120" evidence="22 35 101 104">
<original>T</original>
<variation>N</variation>
<location>
<position position="116"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired ability to cleave Ephb2/CTF1; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; impaired regulation of neurite outgrowth; dbSNP:rs63749805." id="VAR_009209" evidence="55 72 127">
<original>P</original>
<variation>L</variation>
<location>
<position position="117"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; impaired regulation of neurite outgrowth; dbSNP:rs63750550." id="VAR_081233" evidence="55">
<original>P</original>
<variation>S</variation>
<location>
<position position="117"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired protease activity with APP and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751272." id="VAR_006418" evidence="23 101 128">
<original>E</original>
<variation>D</variation>
<location>
<position position="120"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired protease activity with APP and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750800." id="VAR_006419" evidence="101">
<original>E</original>
<variation>K</variation>
<location>
<position position="120"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; uncertain pathological significance; loss of protease activity with APP." id="VAR_070023" evidence="86 101">
<original>L</original>
<variation>R</variation>
<location>
<position position="134"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired protease activity with APP and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750353." id="VAR_010121" evidence="101 122">
<original>N</original>
<variation>D</variation>
<location>
<position position="135"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750522." id="VAR_006420">
<original>M</original>
<variation>I</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63751106." id="VAR_010122" evidence="129">
<original>M</original>
<variation>K</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63751106." id="VAR_006421" evidence="23 115">
<original>M</original>
<variation>T</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751037." id="VAR_006422" evidence="29 101 110">
<original>M</original>
<variation>V</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_081234" evidence="103">
<original>V</original>
<variation>F</variation>
<location>
<position position="142"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750322." id="VAR_006423" evidence="18">
<original>I</original>
<variation>F</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; impaired protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750004." id="VAR_006424" evidence="35 37 56 67 101 114">
<original>I</original>
<variation>T</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750391." id="VAR_006425" evidence="35 50">
<original>M</original>
<variation>I</variation>
<location>
<position position="146"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; disease phenotype shows high clinical variability; founder mutation originating from Southern Italy and distributed worldwide; alters the conformation of the active site; slightly increased protease activity with APP; decreased activity for Notch1 cleavage; no loss of its ability to cleave Ephb2/CTF1; dbSNP:rs63750306." id="VAR_006426" evidence="23 35 72 78 85 101 111">
<original>M</original>
<variation>L</variation>
<location>
<position position="146"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; loss of function as calcium-leak channel; results in calcium overload in the endoplasmic reticulum; dbSNP:rs63750306." id="VAR_006427" evidence="35 69 110">
<original>M</original>
<variation>V</variation>
<location>
<position position="146"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750907." id="VAR_010123" evidence="23 101">
<original>T</original>
<variation>I</variation>
<location>
<position position="147"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP resulting in decreased amyloid-beta 42 and amyloid-beta 40 production; dbSNP:rs63751441." id="VAR_081235" evidence="50 91 101">
<original>L</original>
<variation>V</variation>
<location>
<position position="153"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; dbSNP:rs63751292." id="VAR_081236" evidence="50">
<original>Y</original>
<variation>C</variation>
<location>
<position position="154"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; disease phenotype includes spastic paraparesis; abolishes protease activity with APP resulting in decreased amyloid-beta 42 and amyloid-beta 40 production; dbSNP:rs63750588." id="VAR_081237" evidence="59 101">
<original>Y</original>
<variation>N</variation>
<location>
<position position="154"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_075262" evidence="35">
<original>Y</original>
<variation>FTY</variation>
<location>
<position position="156"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; dbSNP:rs778630379." id="VAR_081238" evidence="88">
<original>Y</original>
<variation>F</variation>
<location>
<position position="159"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; decreased activity for Notch cleavage; dbSNP:rs63750590." id="VAR_006428" evidence="23 35 85 86 101 111 115 117 128">
<original>H</original>
<variation>R</variation>
<location>
<position position="163"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; slightly increased protease activity with APP and slightly increased amyloid-beta 42 production; dbSNP:rs63749885." id="VAR_006429" evidence="101 110">
<original>H</original>
<variation>Y</variation>
<location>
<position position="163"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63751484." id="VAR_010124" evidence="23">
<original>W</original>
<variation>C</variation>
<location>
<position position="165"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; onset in adolescence; severe decrease of protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; results in reduced Notch proteolysis; dbSNP:rs63750265." id="VAR_016216" evidence="45 87 89 101">
<original>L</original>
<variation>P</variation>
<location>
<position position="166"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; abolishes protease activity with APP resulting in decreased amyloid-beta 42 and amyloid-beta 40 production." id="VAR_081239" evidence="50">
<location>
<position position="168"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63751210." id="VAR_006430" evidence="131">
<original>S</original>
<variation>L</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750418." id="VAR_006431" evidence="16 101">
<original>S</original>
<variation>P</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750577." id="VAR_081240" evidence="65 73 101 105">
<original>S</original>
<variation>F</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750963." id="VAR_006432" evidence="50 101 132">
<original>L</original>
<variation>P</variation>
<location>
<position position="171"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750299." id="VAR_010125" evidence="23 101">
<original>L</original>
<variation>W</variation>
<location>
<position position="173"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751144." id="VAR_016217" evidence="48 101">
<original>L</original>
<variation>M</variation>
<location>
<position position="174"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749911." id="VAR_075263" evidence="35 101">
<original>F</original>
<variation>L</variation>
<location>
<position position="177"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; dbSNP:rs63749806." id="VAR_075264" evidence="35">
<original>F</original>
<variation>S</variation>
<location>
<position position="177"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; abolishes protease activity with APP; dbSNP:rs63750155." id="VAR_075265" evidence="35 101">
<original>S</original>
<variation>P</variation>
<location>
<position position="178"/>
</location>
</feature>
<feature type="sequence variant" description="In PIDB and AD3; neuropathologic examination of brain sections from the patient shows the presence of Pick bodies and absence of beta-amyloid plaques; unknown pathological significance; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio in vitro; dbSNP:rs63751068." id="VAR_081241" evidence="56 101">
<original>G</original>
<variation>V</variation>
<location>
<position position="183"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750311." id="VAR_081242" evidence="50 101">
<original>E</original>
<variation>D</variation>
<location>
<position position="184"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1042864." id="VAR_011876">
<original>F</original>
<variation>L</variation>
<location>
<position position="205"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750082." id="VAR_016218" evidence="35 39 100 101">
<original>G</original>
<variation>A</variation>
<location>
<position position="206"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; affects APP processing resulting in increased amyloid-beta 42/amyloid-beta 40 ratio; does not affect NOTCH processing; does not affect endoproteolysis; reduced interaction with PEN2; results in decreased protein levels in the endoplasmic reticulum but increased levels in early endosome; reduced ability to maintain ER calcium homeostasis." id="VAR_081243" evidence="83 94 103">
<original>G</original>
<variation>D</variation>
<location>
<position position="206"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750569." id="VAR_075266" evidence="35 101">
<original>G</original>
<variation>S</variation>
<location>
<position position="206"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_075267" evidence="35">
<original>G</original>
<variation>E</variation>
<location>
<position position="209"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749880." id="VAR_009210" evidence="24 101">
<original>G</original>
<variation>R</variation>
<location>
<position position="209"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750053." id="VAR_006433" evidence="101 128">
<original>G</original>
<variation>V</variation>
<location>
<position position="209"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; increases protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750861." id="VAR_075268" evidence="35 97 101">
<original>I</original>
<variation>L</variation>
<location>
<position position="213"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751309." id="VAR_006434" evidence="74 117">
<original>I</original>
<variation>T</variation>
<location>
<position position="213"/>
</location>
</feature>
<feature type="sequence variant" description="Probable disease-associated variant found in a patient with dementia; dbSNP:rs63751003." id="VAR_070024" evidence="86">
<original>H</original>
<variation>Y</variation>
<location>
<position position="214"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; with unusual amyloid cotton wool plaques; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs267606983." id="VAR_081244" evidence="76 101">
<original>G</original>
<variation>R</variation>
<location>
<position position="217"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750761." id="VAR_010126" evidence="21">
<original>L</original>
<variation>P</variation>
<location>
<position position="219"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; slightly increased protease activity with APP and slightly increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750009." id="VAR_075269" evidence="35 101">
<original>Q</original>
<variation>R</variation>
<location>
<position position="222"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749970." id="VAR_081245" evidence="50 101">
<original>I</original>
<variation>F</variation>
<location>
<position position="229"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749836." id="VAR_006435" evidence="23 35 101 115">
<original>A</original>
<variation>T</variation>
<location>
<position position="231"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750799." id="VAR_006436" evidence="67 124">
<original>A</original>
<variation>V</variation>
<location>
<position position="231"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; slightly decreased protease activity with APP resulting in altered amyloid-beta production and mildly increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751287." id="VAR_009211" evidence="25 35 101">
<original>M</original>
<variation>L</variation>
<location>
<position position="233"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751024." id="VAR_006437" evidence="23 101 120">
<original>M</original>
<variation>T</variation>
<location>
<position position="233"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63749835." id="VAR_006438" evidence="23 35 101">
<original>L</original>
<variation>P</variation>
<location>
<position position="235"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP." id="VAR_081246" evidence="84 101">
<original>L</original>
<variation>R</variation>
<location>
<position position="235"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; reduced APP cleavage resulting in decreased amyloid-beta 42 and amyloid-beta 40 production; no relevant change in amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751130." id="VAR_081247" evidence="50 101">
<original>L</original>
<variation>V</variation>
<location>
<position position="235"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; disease phenotype includes spastic paraparesis; unknown pathological significance; severe decrease of protease activity with APP; results in decreased amyloid-beta 42 and amyloid-beta 40 production; dbSNP:rs63750858." id="VAR_081248" evidence="36 97 101">
<original>F</original>
<variation>I</variation>
<location>
<position position="237"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; dbSNP:rs63750858." id="VAR_081249" evidence="50">
<original>F</original>
<variation>L</variation>
<location>
<position position="237"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; nearly abolishes protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; no loss of its ability to cleave Ephb2/CTF1; dbSNP:rs63750526." id="VAR_006439" evidence="72 101 111">
<original>A</original>
<variation>E</variation>
<location>
<position position="246"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; nearly abolishes protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751163." id="VAR_006440" evidence="101">
<original>L</original>
<variation>S</variation>
<location>
<position position="250"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; nearly abolishes protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; impaired ability to cleave Ephb2/CTF1; dbSNP:rs63751420." id="VAR_006441" evidence="50 72 101 112 128">
<original>A</original>
<variation>V</variation>
<location>
<position position="260"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; nearly abolishes protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750964." id="VAR_075270" evidence="35 97 101">
<original>V</original>
<variation>F</variation>
<location>
<position position="261"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750248." id="VAR_006442" evidence="67 101">
<original>L</original>
<variation>F</variation>
<location>
<position position="262"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3." id="VAR_070025" evidence="86">
<original>L</original>
<variation>V</variation>
<location>
<position position="262"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751102." id="VAR_081250" evidence="50 67">
<original>C</original>
<variation>F</variation>
<location>
<position position="263"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750543." id="VAR_006443" evidence="101">
<original>C</original>
<variation>R</variation>
<location>
<position position="263"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; impaired ability to cleave Ephb2/CTF1; dbSNP:rs63750301." id="VAR_006444" evidence="23 72 101 115 128">
<original>P</original>
<variation>L</variation>
<location>
<position position="264"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; nearly abolishes protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs121917807." id="VAR_016219" evidence="42 101">
<original>G</original>
<variation>S</variation>
<location>
<position position="266"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751229." id="VAR_006445" evidence="101">
<original>P</original>
<variation>S</variation>
<location>
<position position="267"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3." id="VAR_006446" evidence="110">
<original>P</original>
<variation>T</variation>
<location>
<position position="267"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751019." id="VAR_006447" evidence="101">
<original>R</original>
<variation>G</variation>
<location>
<position position="269"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750900." id="VAR_006448" evidence="50">
<original>R</original>
<variation>H</variation>
<location>
<position position="269"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750886." id="VAR_016220" evidence="49 101">
<original>L</original>
<variation>V</variation>
<location>
<position position="271"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; abolishes protease activity with APP; dbSNP:rs63750284." id="VAR_075271" evidence="35 101">
<original>T</original>
<variation>R</variation>
<location>
<position position="274"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; reduced protease activity with APP resulting in reduced amyloid-beta 40 levels but no relevant changes in amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs1555355869." id="VAR_081251" evidence="92 101">
<original>A</original>
<variation>V</variation>
<location>
<position position="275"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; atypical phenotype presenting as language impairment, impaired frontal executive function and relative preservation of memory; severe decrease of APP and Notch proteolysis; dbSNP:rs63749891." id="VAR_081252" evidence="61 89">
<original>R</original>
<variation>I</variation>
<location>
<position position="278"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63749891." id="VAR_006449" evidence="120">
<original>R</original>
<variation>T</variation>
<location>
<position position="278"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; strong deposition of amyloid-beta 42 is observed in brain regions of AD3 patients; decreased protease activity with APP resulting in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; decreased activity for Notch1 cleavage; dbSNP:rs63750231." id="VAR_006450" evidence="37 85 101 102 110 118 123">
<original>E</original>
<variation>A</variation>
<location>
<position position="280"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; some AD3 patients manifest spastic paraparesis and unusual amyloid plaques with prominent amyloid angiopathy on brain biopsy; decreased protease activity with APP; increased amyloid-beta 42/amyloid-beta 40 ratio; impaired ability to cleave Ephb2/CTF1; dbSNP:rs63750231." id="VAR_006451" evidence="47 72 101 110">
<original>E</original>
<variation>G</variation>
<location>
<position position="280"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750050." id="VAR_009212" evidence="25 101">
<original>L</original>
<variation>R</variation>
<location>
<position position="282"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749937." id="VAR_081253" evidence="38 56 67">
<original>L</original>
<variation>V</variation>
<location>
<position position="282"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; slightly decreased protease activity with APP and slightly decreased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751139." id="VAR_006452" evidence="101 112">
<original>A</original>
<variation>V</variation>
<location>
<position position="285"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751235." id="VAR_006453" evidence="101 111">
<original>L</original>
<variation>V</variation>
<location>
<position position="286"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3." id="VAR_010127">
<original>S</original>
<variation>C</variation>
<location>
<position position="289"/>
</location>
</feature>
<feature type="sequence variant" description="Probable disease-associated variant found in patients with late-onset Alzheimer disease; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs115865530." id="VAR_081254" evidence="102">
<original>K</original>
<variation>R</variation>
<location>
<position position="311"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a renal cell carcinoma sample; somatic mutation." id="VAR_064747" evidence="82">
<original>Y</original>
<variation>C</variation>
<location>
<position position="315"/>
</location>
</feature>
<feature type="sequence variant" description="Polymorphism; dbSNP:rs17125721." id="VAR_006454" evidence="23 25 29 35 37 50 75 124 133 134 135">
<original>E</original>
<variation>G</variation>
<location>
<position position="318"/>
</location>
</feature>
<feature type="sequence variant" description="In CMD1U; results in slightly decreased protease activity with APP and slightly decreased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs121917809." id="VAR_064902" evidence="70 101">
<original>D</original>
<variation>G</variation>
<location>
<position position="333"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_075272" evidence="35">
<original>R</original>
<variation>RR</variation>
<location>
<position position="352"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; results in decreased protease activity with APP and decreased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751164." id="VAR_075273" evidence="35 101">
<original>T</original>
<variation>I</variation>
<location>
<position position="354"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751174." id="VAR_075274" evidence="35 101">
<original>R</original>
<variation>Q</variation>
<location>
<position position="358"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; dbSNP:rs63750941." id="VAR_075275" evidence="35">
<original>S</original>
<variation>Y</variation>
<location>
<position position="365"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_081255" evidence="50">
<original>R</original>
<variation>M</variation>
<location>
<position position="377"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio." id="VAR_006455" evidence="19 101">
<original>G</original>
<variation>E</variation>
<location>
<position position="378"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750323." id="VAR_081256" evidence="50 100 101">
<original>G</original>
<variation>V</variation>
<location>
<position position="378"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs63750687." id="VAR_081257" evidence="90">
<original>L</original>
<variation>F</variation>
<location>
<position position="381"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750687." id="VAR_081258" evidence="77 101">
<original>L</original>
<variation>V</variation>
<location>
<position position="381"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in reduced APP and Notch proteolysis; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750646." id="VAR_006456" evidence="67 89 101 114">
<original>G</original>
<variation>A</variation>
<location>
<position position="384"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; abolishes protease activity with APP; dbSNP:rs63750883." id="VAR_010128" evidence="23 101">
<original>S</original>
<variation>I</variation>
<location>
<position position="390"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in reduced APP and Notch proteolysis; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63751416." id="VAR_006457" evidence="23 89 101 112 115">
<original>L</original>
<variation>V</variation>
<location>
<position position="392"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; abolishes protease activity with APP; dbSNP:rs63750929." id="VAR_075276" evidence="35 101">
<original>G</original>
<variation>V</variation>
<location>
<position position="394"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; decreased protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio." id="VAR_070026" evidence="101">
<original>A</original>
<variation>T</variation>
<location>
<position position="396"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; decreased protease activity with APP; dbSNP:rs63751254." id="VAR_010129" evidence="30 101">
<original>N</original>
<variation>S</variation>
<location>
<position position="405"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; dbSNP:rs906454643." id="VAR_075277" evidence="98">
<original>I</original>
<variation>T</variation>
<location>
<position position="408"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; decreased protease activity with APP; dbSNP:rs63750227." id="VAR_009213" evidence="25 101">
<original>A</original>
<variation>T</variation>
<location>
<position position="409"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; results in reduced APP and Notch proteolysis; dbSNP:rs661." id="VAR_006458" evidence="23 89 101 115 128">
<original>C</original>
<variation>Y</variation>
<location>
<position position="410"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance." id="VAR_081259" evidence="106">
<original>G</original>
<variation>A</variation>
<location>
<position position="417"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; nearly abolishes protease activity with APP; dbSNP:rs63751316." id="VAR_075278" evidence="35 101">
<original>L</original>
<variation>F</variation>
<location>
<position position="418"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; slightly decreased protease activity with APP; dbSNP:rs63751223." id="VAR_006459" evidence="101 128">
<original>A</original>
<variation>P</variation>
<location>
<position position="426"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; decreased protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63750083." id="VAR_025605" evidence="35 66 68 101 136">
<original>A</original>
<variation>E</variation>
<location>
<position position="431"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; with unusual amyloid cotton wool plaques; almost abolishes gamma-secretase activity; no endoproteolytic cleavage; no APP nor NOTCH1 processing; no detectable amyloid-beta; dbSNP:rs63750001." id="VAR_075280" evidence="35 64 79 89 101">
<original>L</original>
<variation>F</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; severe decrease of protease activity with APP; dbSNP:rs121917808." id="VAR_006460" evidence="87 131">
<original>P</original>
<variation>Q</variation>
<location>
<position position="436"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; partially abolishes gamma-secretase activity; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP:rs63749925." id="VAR_008141" evidence="18 82 101">
<original>P</original>
<variation>S</variation>
<location>
<position position="436"/>
</location>
</feature>
<feature type="sequence variant" description="In AD3; unknown pathological significance; no significant change of protease activity with APP; dbSNP:rs63750249." id="VAR_075282" evidence="35 101">
<original>I</original>
<variation>V</variation>
<location>
<position position="439"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on interaction with GFAP." evidence="46">
<location>
<begin position="66"/>
<end position="72"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on interaction with GFAP." evidence="46">
<original>KY</original>
<variation>AA</variation>
<location>
<begin position="76"/>
<end position="77"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of interaction with GFAP." evidence="46">
<original>VI</original>
<variation>EE</variation>
<location>
<begin position="82"/>
<end position="83"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of interaction with GFAP." evidence="46">
<original>V</original>
<variation>K</variation>
<variation>E</variation>
<location>
<position position="82"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of interaction with GFAP." evidence="46">
<original>ML</original>
<variation>EE</variation>
<location>
<begin position="84"/>
<end position="85"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>T</original>
<variation>A</variation>
<location>
<position position="99"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>F</original>
<variation>I</variation>
<location>
<position position="105"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>R</original>
<variation>Q</variation>
<location>
<position position="108"/>
</location>
</feature>
<feature type="mutagenesis site" description="Formation of an artifactual disulfide bond with a substrate protein." evidence="108 109">
<original>Q</original>
<variation>C</variation>
<location>
<position position="112"/>
</location>
</feature>
<feature type="mutagenesis site" description="Severe decrease of protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>L</original>
<variation>Q</variation>
<location>
<position position="113"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>P</original>
<variation>A</variation>
<location>
<position position="117"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>E</original>
<variation>K</variation>
<location>
<position position="123"/>
</location>
</feature>
<feature type="mutagenesis site" description="Severe decrease of protease activity with APP." evidence="101">
<original>H</original>
<variation>R</variation>
<location>
<position position="131"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP." evidence="101">
<original>A</original>
<variation>G</variation>
<location>
<position position="136"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>I</original>
<variation>V</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>L</original>
<variation>P</variation>
<location>
<position position="150"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>W</original>
<variation>G</variation>
<location>
<position position="165"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>I</original>
<variation>T</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>F</original>
<variation>L</variation>
<location>
<position position="176"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>E</original>
<variation>G</variation>
<location>
<position position="184"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="97 101">
<original>I</original>
<variation>F</variation>
<location>
<position position="202"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>S</original>
<variation>Y</variation>
<location>
<position position="212"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>H</original>
<variation>D</variation>
<location>
<position position="214"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>L</original>
<variation>F</variation>
<location>
<position position="219"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>Q</original>
<variation>R</variation>
<location>
<position position="223"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increases protease activity with APP." evidence="97 101">
<original>L</original>
<variation>F</variation>
<location>
<position position="226"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>S</original>
<variation>I</variation>
<location>
<position position="230"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>I</original>
<variation>M</variation>
<location>
<position position="238"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>K</original>
<variation>N</variation>
<location>
<position position="239"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>T</original>
<variation>P</variation>
<location>
<position position="245"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="97 101">
<original>L</original>
<variation>R</variation>
<location>
<position position="248"/>
</location>
</feature>
<feature type="mutagenesis site" description="Alters gamma-secretase cleavage specificity. Increased production of amyloid-beta protein 42. No effect on enzymatic activity." evidence="58">
<original>Y</original>
<variation>F</variation>
<location>
<position position="256"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>Y</original>
<variation>S</variation>
<location>
<position position="256"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impaired ability to cleave Ephb2/CTF1." evidence="72">
<original>D</original>
<variation>A</variation>
<location>
<position position="257"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of endoproteolytic cleavage. Severe decrease of protease activity with APP. Reduces production of amyloid-beta. Reduces production of NICD in NOTCH1 processing." evidence="20 32 58 87">
<original>D</original>
<variation>A</variation>
<location>
<position position="257"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes gamma-secretase activity. Reduces production of amyloid-beta in APP processing. Accumulation of full-length PS1. Loss of binding of transition state analog gamma-secretase inhibitor." evidence="20 32 58">
<original>D</original>
<variation>E</variation>
<location>
<position position="257"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>V</original>
<variation>A</variation>
<location>
<position position="272"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>E</original>
<variation>A</variation>
<location>
<position position="273"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>R</original>
<variation>K</variation>
<location>
<position position="278"/>
</location>
</feature>
<feature type="mutagenesis site" description="No significant change of protease activity with APP." evidence="101">
<original>P</original>
<variation>S</variation>
<location>
<position position="284"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increases production of amyloid-beta in APP processing." evidence="31">
<original>L</original>
<variation>A</variation>
<variation>E</variation>
<variation>P</variation>
<variation>Q</variation>
<variation>R</variation>
<variation>W</variation>
<location>
<position position="286"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces production of NICD in NOTCH1 processing." evidence="31">
<original>L</original>
<variation>E</variation>
<variation>R</variation>
<location>
<position position="286"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of NOTCH1 and APP C83 cleavage." evidence="108 109">
<location>
<begin position="288"/>
<end position="290"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>T</original>
<variation>P</variation>
<location>
<position position="291"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of endoproteolytic cleavage." evidence="26">
<original>M</original>
<variation>D</variation>
<location>
<position position="292"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PKA-mediated phosphorylation; no effect on caspase-mediated cleavage." evidence="54">
<original>S</original>
<variation>A</variation>
<location>
<position position="310"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes caspase cleavage." evidence="126">
<original>D</original>
<variation>N</variation>
<location>
<position position="345"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PKC-mediated phosphorylation; no effect on PKA-mediated phosphorylation." evidence="54">
<original>S</original>
<variation>A</variation>
<location>
<position position="346"/>
</location>
</feature>
<feature type="mutagenesis site" description="Inhibits caspase-mediated cleavage. Modulates progression of apoptosis." evidence="54">
<original>S</original>
<variation>E</variation>
<location>
<position position="346"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP." evidence="101">
<original>R</original>
<variation>C</variation>
<location>
<position position="352"/>
</location>
</feature>
<feature type="mutagenesis site" description="Slightly increased protease activity with APP." evidence="101">
<original>S</original>
<variation>A</variation>
<location>
<position position="365"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on caspase cleavage." evidence="126">
<original>D</original>
<variation>N</variation>
<location>
<position position="373"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of NOTCH1 and APP C83 cleavage." evidence="108 109">
<location>
<begin position="377"/>
<end position="381"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP." evidence="101">
<original>R</original>
<variation>W</variation>
<location>
<position position="377"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of endoproteolytic cleavage. Severe decrease of protease activity with APP. Reduces production of amyloid-beta. Loss of NOTCH1 cleavage. Disassembly of the N-cadherin/PS1 complex at the cell surface. Impairs CDH2 processing." evidence="20 32 53 58 87 108 109 126">
<original>D</original>
<variation>A</variation>
<location>
<position position="385"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes gamma-secretase activity. Reduces production of amyloid-beta in APP processing. Accumulation of full-length PS1. Loss of binding of transition state analog gamma-secretase inhibitor." evidence="20 32 53 58 126">
<original>D</original>
<variation>E</variation>
<location>
<position position="385"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on caspase cleavage." evidence="20 32 53 58 126">
<original>D</original>
<variation>N</variation>
<location>
<position position="385"/>
</location>
</feature>
<feature type="mutagenesis site" description="Nearly abolishes protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>F</original>
<variation>S</variation>
<location>
<position position="386"/>
</location>
</feature>
<feature type="mutagenesis site" description="Alters gamma-secretase cleavage specificity. Increased production of amyloid-beta protein 42. No effect on enzymatic activity." evidence="58">
<original>Y</original>
<variation>F</variation>
<location>
<position position="389"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP." evidence="101">
<original>V</original>
<variation>F</variation>
<location>
<position position="391"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes protease activity with APP." evidence="101">
<original>V</original>
<variation>I</variation>
<location>
<position position="412"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>L</original>
<variation>R</variation>
<location>
<position position="420"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increases protease activity with APP." evidence="97 101">
<original>L</original>
<variation>V</variation>
<location>
<position position="424"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of NOTCH1 and APP C83 cleavage." evidence="108 109">
<location>
<begin position="432"/>
<end position="434"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of NOTCH1 and APP C83 cleavage." evidence="108 109">
<original>L</original>
<variation>P</variation>
<location>
<position position="432"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on endoproteolytic cleavage. No effect on APP nor NOTCH1 processing. Slightly increased amyloid-beta protein 42/40 ratio." evidence="64">
<original>P</original>
<variation>A</variation>
<location>
<position position="433"/>
</location>
</feature>
<feature type="mutagenesis site" description="No endoproteolytic cleavage; no APP, nor NOTCH1 processing. No detectable amyloid-beta." evidence="64 79">
<original>P</original>
<variation>D</variation>
<variation>F</variation>
<variation>L</variation>
<variation>N</variation>
<variation>V</variation>
<location>
<position position="433"/>
</location>
</feature>
<feature type="mutagenesis site" description="Very little endoproteolysis. Little APP processing. No NOTCH1 processing. Very low levels amyloid-beta protein 40 and no detectable amyloid-beta protein 42." evidence="64">
<original>P</original>
<variation>G</variation>
<location>
<position position="433"/>
</location>
</feature>
<feature type="mutagenesis site" description="Some loss of endoproteolytic cleavage. Some loss of APP and NOTCH1 processing. 6 to 13-fold increase in amyloid-beta protein 42/40 ratio." evidence="64 101">
<original>A</original>
<variation>C</variation>
<location>
<position position="434"/>
</location>
</feature>
<feature type="mutagenesis site" description="No endoproteolytic cleavage. No APP nor NOTCH1 processing. No detectable amyloid-beta." evidence="64">
<original>A</original>
<variation>D</variation>
<variation>I</variation>
<variation>L</variation>
<variation>V</variation>
<location>
<position position="434"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on endoproteolytic cleavage. No effect on APP nor NOTCH1 processing. Reduced amyloid-beta protein 42/40 ratio." evidence="64">
<original>A</original>
<variation>G</variation>
<location>
<position position="434"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on endoproteolytic cleavage. No effect on APP processing. Impaired NOTCH1 processing. Greatly reduced amyloid-beta protein 42/40 ratio." evidence="64">
<original>L</original>
<variation>A</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="mutagenesis site" description="Greatly reduced endoproteolytic cleavage. Very little APP and NOTCH1 processing. Very low levels of amyloid-beta protein 40 and no detectable amyloid-beta protein 42." evidence="64">
<original>L</original>
<variation>G</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on endoproteolytic cleavage. No effect on APP nor NOTCH1 processing." evidence="64">
<original>L</original>
<variation>I</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="mutagenesis site" description="No endoproteolytic cleavage; no APP, nor NOTCH1 processing. No detectable amyloid-beta." evidence="79">
<original>L</original>
<variation>R</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on endoproteolytic cleavage. No effect on APP processing. Impaired NOTCH1 processing. Some increase in amyloid-beta protein 42/40 ratio." evidence="64">
<original>L</original>
<variation>V</variation>
<location>
<position position="435"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro." evidence="101">
<original>I</original>
<variation>V</variation>
<location>
<position position="437"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAL16811." ref="7" evidence="142">
<original>R</original>
<variation>G</variation>
<location>
<position position="128"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="74"/>
<end position="102"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="105"/>
<end position="107"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="120"/>
<end position="123"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="125"/>
<end position="155"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="159"/>
<end position="175"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="177"/>
<end position="188"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="195"/>
<end position="214"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="219"/>
<end position="239"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="243"/>
<end position="262"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="263"/>
<end position="266"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="269"/>
<end position="277"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="278"/>
<end position="280"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="284"/>
<end position="289"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="293"/>
<end position="299"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="341"/>
<end position="345"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="356"/>
<end position="368"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="378"/>
<end position="382"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="383"/>
<end position="398"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="401"/>
<end position="404"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="405"/>
<end position="428"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="432"/>
<end position="435"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="438"/>
<end position="449"/>
</location>
</feature>
<feature type="turn" evidence="9">
<location>
<begin position="450"/>
<end position="452"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="453"/>
<end position="463"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2KR6"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4UIS"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5A63"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5FN2"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5FN3"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5FN4"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5FN5"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6IDF"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6IYC"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="17081983"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P49769"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P97887"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q4JIM4"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10025789"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10037471"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10090481"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10200054"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10206644"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10208579"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10439444"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10441572"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10447269"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10533070"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10545183"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10551805"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10593990"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10631141"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10644793"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10811883"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10899933"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11027672"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11094121"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11524469"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11561050"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11568920"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11701593"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11710891"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11796781"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11799129"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11920851"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11953314"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11987239"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12048239"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12058025"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12370477"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12484344"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12493737"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12552037"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12679784"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12740439"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14515347"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14576165"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15004326"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15122701"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15274632"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15341515"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15364419"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15534188"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15534260"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15851849"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16126725"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16305624"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16344340"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16628450"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16752394"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16897084"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16959576"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17186461"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17366635"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17428795"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17502474"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18430735"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18485326"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19667325"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19797784"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20164095"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20460383"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20929727"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21143716"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21248752"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21335660"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21501661"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22461631"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22503161"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22529981"/>
</source>
</evidence>
<evidence key="88" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23123781"/>
</source>
</evidence>
<evidence key="89" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23843529"/>
</source>
</evidence>
<evidence key="90" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24121961"/>
</source>
</evidence>
<evidence key="91" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24495933"/>
</source>
</evidence>
<evidence key="92" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24582897"/>
</source>
</evidence>
<evidence key="93" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25043039"/>
</source>
</evidence>
<evidence key="94" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25394380"/>
</source>
</evidence>
<evidence key="95" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25918421"/>
</source>
</evidence>
<evidence key="96" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26145164"/>
</source>
</evidence>
<evidence key="97" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26280335"/>
</source>
</evidence>
<evidence key="98" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26549787"/>
</source>
</evidence>
<evidence key="99" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26623517"/>
</source>
</evidence>
<evidence key="100" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27073747"/>
</source>
</evidence>
<evidence key="101" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27930341"/>
</source>
</evidence>
<evidence key="102" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28269784"/>
</source>
</evidence>
<evidence key="103" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29175279"/>
</source>
</evidence>
<evidence key="104" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29404783"/>
</source>
</evidence>
<evidence key="105" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29466804"/>
</source>
</evidence>
<evidence key="106" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30180983"/>
</source>
</evidence>
<evidence key="107" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30200536"/>
</source>
</evidence>
<evidence key="108" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30598546"/>
</source>
</evidence>
<evidence key="109" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30630874"/>
</source>
</evidence>
<evidence key="110" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7550356"/>
</source>
</evidence>
<evidence key="111" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7596406"/>
</source>
</evidence>
<evidence key="112" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7651536"/>
</source>
</evidence>
<evidence key="113" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8574969"/>
</source>
</evidence>
<evidence key="114" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8634711"/>
</source>
</evidence>
<evidence key="115" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8634712"/>
</source>
</evidence>
<evidence key="116" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8641442"/>
</source>
</evidence>
<evidence key="117" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8733303"/>
</source>
</evidence>
<evidence key="118" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8837617"/>
</source>
</evidence>
<evidence key="119" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9144240"/>
</source>
</evidence>
<evidence key="120" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9172170"/>
</source>
</evidence>
<evidence key="121" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9173929"/>
</source>
</evidence>
<evidence key="122" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9225696"/>
</source>
</evidence>
<evidence key="123" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9298817"/>
</source>
</evidence>
<evidence key="124" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9384602"/>
</source>
</evidence>
<evidence key="125" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9437013"/>
</source>
</evidence>
<evidence key="126" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9485372"/>
</source>
</evidence>
<evidence key="127" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9507958"/>
</source>
</evidence>
<evidence key="128" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9521423"/>
</source>
</evidence>
<evidence key="129" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9719376"/>
</source>
</evidence>
<evidence key="130" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9738936"/>
</source>
</evidence>
<evidence key="131" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9831473"/>
</source>
</evidence>
<evidence key="132" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9833068"/>
</source>
</evidence>
<evidence key="133" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9851443"/>
</source>
</evidence>
<evidence key="134" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9851450"/>
</source>
</evidence>
<evidence key="135" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9915968"/>
</source>
</evidence>
<evidence key="136" type="ECO:0000269">
<source ref="92"/>
</evidence>
<evidence key="137" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="138" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="7596406"/>
</source>
</evidence>
<evidence key="139" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="8641442"/>
</source>
</evidence>
<evidence key="140" type="ECO:0000303">
<source ref="3"/>
</evidence>
<evidence key="141" type="ECO:0000303">
<source ref="5"/>
</evidence>
<evidence key="142" type="ECO:0000305"/>
<evidence key="143" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="10037471"/>
</source>
</evidence>
<evidence key="144" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="10206644"/>
</source>
</evidence>
<evidence key="145" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="10899933"/>
</source>
</evidence>
<evidence key="146" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="15274632"/>
</source>
</evidence>
<evidence key="147" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="15341515"/>
</source>
</evidence>
<evidence key="148" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="16305624"/>
</source>
</evidence>
<evidence key="149" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="25394380"/>
</source>
</evidence>
<evidence key="150" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="30598546"/>
</source>
</evidence>
<evidence key="151" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="30630874"/>
</source>
</evidence>
<sequence length="467" mass="52668" checksum="5E0F451EF82BCF20" modified="1996-10-01" version="1">MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVVVATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWTAWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

